John M. Kane
#65,024
Most Influential Person Now
International leader in the field of schizophrenia research
John M. Kane's AcademicInfluence.com Rankings
Download Badge
Biology
Why Is John M. Kane Influential?
(Suggest an Edit or Addition)According to Wikipedia, John M. Kane is an American psychiatrist who served as the Chair of Psychiatry at the Zucker Hillside Hospital for 34 years. He also served as the Chair of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell for its first 12 years. He stepped down from these roles in 2022 to focus his efforts on his research and mentorship of early career investigators as Co-Director, Institute of Behavioral Science at the Feinstein Institutes for Medical Research, part of Northwell Health.
John M. Kane's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Remission in schizophrenia: proposed criteria and rationale for consensus. (2005) (2004)
- The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test-retest reliability. (1992) (1609)
- What does the PANSS mean? (2005) (991)
- Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. (2000) (932)
- Extending indications for long-term pharmacotherapy: opportunities and challenges. (2002) (920)
- Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. (2009) (910)
- Research diagnoses for tardive dyskinesia. (1982) (902)
- Physical health monitoring of patients with schizophrenia. (2004) (829)
- Clinical implications of Brief Psychiatric Rating Scale scores. (2005) (710)
- Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. (2004) (641)
- Tardive dyskinesia: prevalence and risk factors, 1959 to 1979 (1982) (631)
- Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. (2002) (570)
- Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. (2017) (567)
- Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program. (2016) (538)
- The Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-II). II: Multi-site test-retest reliability study (1995) (478)
- Provocative tests with psychostimulant drugs in schizophrenia (2004) (463)
- Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. (2003) (456)
- Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. (2004) (444)
- Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. (2003) (439)
- The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. (2003) (414)
- Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? (2007) (403)
- Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. (1989) (400)
- Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. (1994) (396)
- Brain-derived neurotrophic factor Val66met polymorphism and volume of the hippocampal formation (2005) (389)
- Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. (2013) (386)
- Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression (2018) (384)
- Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. (2009) (373)
- Non‐adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies (2013) (357)
- Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia (2007) (354)
- Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. (2014) (341)
- Improving outcomes of first‐episode psychosis: an overview (2017) (321)
- Objective User Engagement With Mental Health Apps: Systematic Search and Panel-Based Usage Analysis (2019) (319)
- Treatment of schizophrenia. (1987) (315)
- Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. (2014) (313)
- Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. (1995) (312)
- Guidelines for depot antipsychotic treatment in schizophrenia (1998) (312)
- Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. (1997) (310)
- Tetrahedron report number 638 Recent advances in the synthesis of piperidones and piperidines (2003) (307)
- Oral versus depot antipsychotic drugs for schizophrenia—A critical systematic review and meta-analysis of randomised long-term trials (2011) (299)
- Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia (2007) (297)
- Attention-deficit/hyperactivity disorder: A preliminary diffusion tensor imaging study (2005) (295)
- Standardized remission criteria in schizophrenia (2006) (282)
- Update on the clinical efficacy and side effects of clozapine. (1991) (271)
- Linking the PANSS, BPRS, and CGI: Clinical Implications (2006) (267)
- Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories (2016) (263)
- Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. (2015) (258)
- Tardive dyskinesia: prevalence, incidence, and risk factors. (1988) (251)
- Does antipsychotic polypharmacy increase the risk for metabolic syndrome? (2007) (247)
- Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia. (2015) (246)
- Psychopharmacologic treatment of schizophrenia. (1993) (245)
- Prospective study of tardive dyskinesia in the elderly: rates and risk factors. (1998) (242)
- Clinical and Neuropsychological Correlates of White Matter Abnormalities in Recent Onset Schizophrenia (2008) (235)
- Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. (1983) (235)
- Clozapine: guidelines for clinical management. (1989) (232)
- The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. (2016) (226)
- Clozapine in treatment-resistant schizophrenics. (1988) (225)
- Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009 (2012) (223)
- Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. (2007) (218)
- Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. (2006) (217)
- Past and present progress in the pharmacologic treatment of schizophrenia. (2010) (216)
- Integrating incidence and prevalence of tardive dyskinesia. (1986) (215)
- Partial compliance and patient consequences in schizophrenia: our patients can do better. (2003) (210)
- Clozapine and weight gain. (1994) (209)
- Early-Onset Hypothesis of Antipsychotic Drug Action: A Hypothesis Tested, Confirmed and Extended (2005) (208)
- Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. (2013) (205)
- HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. (1990) (202)
- Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. (1995) (201)
- CrossCheck: toward passive sensing and detection of mental health changes in people with schizophrenia (2016) (201)
- White matter abnormalities in first-episode schizophrenia or schizoaffective disorder: a diffusion tensor imaging study. (2005) (201)
- Clozapine and “High-Dose” Olanzapine in Refractory Early-Onset Schizophrenia: A 12-Week Randomized and Double-Blind Comparison (2008) (199)
- Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. (2010) (197)
- Pharmacologic treatment of schizophrenia (1999) (195)
- Drug therapy : schizophrenia (1996) (192)
- Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. (1995) (192)
- Definitions of response and remission in schizophrenia: recommendations for their use and their presentation (2009) (190)
- Genetic variation in DTNBP1 influences general cognitive ability. (2006) (188)
- Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. (2012) (187)
- Electrophysiological Indices of Automatic and Controlled Auditory Information Processing in First-Episode, Recent-Onset and Chronic Schizophrenia (2006) (185)
- Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? (2013) (182)
- Subsyndromal symptoms in bipolar disorder. A comparison of standard and low serum levels of lithium. (1992) (181)
- Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. (2012) (181)
- Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics (2005) (179)
- Differentiation in the preonset phases of schizophrenia and mood disorders: evidence in support of a bipolar mania prodrome. (2007) (178)
- Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. (2013) (178)
- Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. (2001) (177)
- What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia? (2018) (175)
- Prospective study of tardive dyskinesia incidence in the elderly. (1991) (175)
- 2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents. (1988) (174)
- Optimizing pharmacologic treatment of psychotic disorders (2003) (173)
- Early prediction of antipsychotic response in schizophrenia. (2003) (173)
- Association of the DTNBP1 locus with schizophrenia in a U.S. population. (2004) (171)
- Defining ‘Response’ in Antipsychotic Drug Trials: Recommendations for the Use of Scale-Derived Cutoffs (2007) (171)
- Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis. (2017) (168)
- The prevalence of tardive dyskinesia. (1991) (167)
- Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia (2010) (166)
- Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. (2009) (163)
- Smaller anterior hippocampal formation volume in antipsychotic-naive patients with first-episode schizophrenia. (2003) (160)
- The NAVIGATE Program for First-Episode Psychosis: Rationale, Overview, and Description of Psychosocial Components. (2015) (159)
- Safety and tolerability of antipsychotic polypharmacy (2012) (159)
- Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment. (2015) (157)
- Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. (2008) (154)
- DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. (2006) (153)
- Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. (2001) (152)
- Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. (2000) (151)
- Depot neuroleptic therapy: an underutilized treatment option. (1992) (150)
- Strategies for mHealth Research: Lessons from 3 Mobile Intervention Studies (2015) (148)
- Akathisia: an updated review focusing on second-generation antipsychotics. (2009) (148)
- Efficacy and Safety of Donepezil in Patients with Schizophrenia or Schizoaffective Disorder: Significant Placebo/Practice Effects in a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial (2008) (147)
- Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia (2008) (147)
- Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics (2011) (145)
- Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta‐analysis and meta‐regression analysis (2017) (142)
- When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature (2012) (141)
- Clinical guideline recommendations for antipsychotic long-acting injections (2009) (141)
- Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. (2005) (140)
- Cognitive Development in Schizophrenia: Follow-Back from the First Episode (2006) (137)
- Does clozapine cause tardive dyskinesia? (1993) (137)
- Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial (2015) (136)
- Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study (2014) (135)
- Treatment of the schizophrenia prodrome: is it presently ethical? (2001) (135)
- Clinical Efficacy of Clozapine in Treatment-Refractory Schizophrenia: An Overview (1992) (135)
- Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis. (2016) (135)
- Treatment of neuroleptic-resistant schizophrenic relapse. (1993) (134)
- Inverse relationship between body mass index and mortality in older nursing home residents: a meta‐analysis of 19,538 elderly subjects (2015) (134)
- Pharmacological treatments for first-episode schizophrenia. (2005) (134)
- Tardive dyskinesia: prevalence, incidence, and risk factors. (1988) (134)
- COMT genetic variation confers risk for psychotic and affective disorders: a case control study (2005) (133)
- Outcome study of first-episode psychosis. I: Relapse rates after 1 year. (1986) (132)
- A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia (2015) (131)
- Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs. (1988) (130)
- Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. (2015) (129)
- The Mount Sinai conference on the pharmacotherapy of schizophrenia. (2002) (129)
- Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection (2005) (128)
- Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence (2017) (127)
- White matter abnormalities in early-onset schizophrenia: a voxel-based diffusion tensor imaging study. (2005) (127)
- Lithium treatment of acute mania in adolescents: a large open trial. (2003) (126)
- Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies (2018) (126)
- Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. (2007) (125)
- CrossCheck: Integrating Self-Report, Behavioral Sensing, and Smartphone Use to Identify Digital Indicators of Psychotic Relapse (2017) (125)
- Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. (2013) (125)
- Treatment-resistant schizophrenic patients. (1996) (123)
- Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. (2011) (123)
- A Collaborative Approach to Identifying Social Media Markers of Schizophrenia by Employing Machine Learning and Clinical Appraisals (2017) (122)
- A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. (2009) (121)
- Tardive dyskinesia in affective disorders. (1999) (121)
- Clozapine for the treatment-resistant schizophrenic: results of a US multicenter trial (1989) (121)
- Early prediction of antipsychotic nonresponse among patients with schizophrenia. (2007) (121)
- The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research (2020) (121)
- Dysbindin genotype and negative symptoms in schizophrenia. (2006) (120)
- Treatment strategies to prevent relapse and encourage remission. (2007) (120)
- Enlight: A Comprehensive Quality and Therapeutic Potential Evaluation Tool for Mobile and Web-Based eHealth Interventions (2017) (119)
- The rationale and ethics of medication-free research in schizophrenia. (1997) (118)
- Dose response of prophylactic antipsychotics. (1993) (117)
- Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? (2007) (116)
- Extrapyramidal side effects are unacceptable (2001) (116)
- Efficacy and Safety of Asenapine in a Placebo- and Haloperidol-Controlled Trial in Patients With Acute Exacerbation of Schizophrenia (2010) (116)
- Incidence of tardive dyskinesia: five-year data from a prospective study. (1984) (115)
- Early identification and high-risk strategies for bipolar disorder. (2007) (114)
- Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. (2006) (113)
- Compliance Issues in Outpatient Treatment (1985) (112)
- Remission in prognosis of functional outcome: A new dimension in the treatment of patients with psychotic disorders (2007) (111)
- Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. (2004) (111)
- Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. (2019) (111)
- Role of social media and the Internet in pathways to care for adolescents and young adults with psychotic disorders and non‐psychotic mood disorders (2017) (110)
- Mobile Behavioral Sensing for Outpatients and Inpatients With Schizophrenia. (2016) (110)
- DISC1 and neurocognitive function in schizophrenia (2005) (108)
- White Matter Changes Associated with Antipsychotic Treatment in First-Episode Psychosis (2014) (107)
- Psychotic syndromes in epilepsy. (1985) (107)
- Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. (1998) (106)
- Review of treatments that can ameliorate nonadherence in patients with schizophrenia. (2006) (105)
- Prediction of relapse in schizophrenia. (1987) (104)
- Cost-Effectiveness of Comprehensive, Integrated Care for First Episode Psychosis in the NIMH RAISE Early Treatment Program. (2016) (103)
- Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis. (2019) (102)
- Genome-wide association study implicates NDST3 in schizophrenia and bipolar disorder (2013) (102)
- The RAISE early treatment program for first-episode psychosis: background, rationale, and study design. (2015) (102)
- DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia (2008) (101)
- The current status of neuroleptic therapy. (1989) (100)
- Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study (2013) (100)
- Adjunctive antipsychotic treatment of adolescents with bipolar psychosis. (2001) (99)
- Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia (2007) (98)
- Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics (2016) (98)
- Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. (2014) (97)
- A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. (2015) (97)
- The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder (2013) (95)
- Tardive dyskinesia risk with first‐ and second‐generation antipsychotics in comparative randomized controlled trials: a meta‐analysis (2018) (95)
- Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. (2005) (95)
- Treatment Adherence and Long-Term Outcomes (2007) (94)
- Sex differences in frontal lobe white matter microstructure: a DTI study (2003) (93)
- Clinical risk factors for the development of tardive dyskinesia (2018) (93)
- Incidence and Correlates of Tardive Dyskinesia in First Episode of Schizophrenia (1996) (93)
- Impairments in perceptual competency and maintenance on a visual delayed match-to-sample test in first-episode schizophrenia. (2003) (92)
- Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. (2021) (92)
- Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin. (1990) (91)
- Schizophrenics with tardive dyskinesia. Neuropsychological deficit and family psychopathology. (1985) (91)
- A user’ guide to clozapine (2011) (91)
- Duration of Untreated Psychosis in Community Treatment Settings in the United States. (2015) (90)
- mHealth for Schizophrenia: Patient Engagement With a Mobile Phone Intervention Following Hospital Discharge (2016) (90)
- Methodological issues in current antipsychotic drug trials. (2007) (90)
- Quantifying clinical relevance in the treatment of schizophrenia. (2011) (89)
- The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia. (1989) (89)
- Long-Term Efficacy and Safety of Iloperidone: Results From 3 Clinical Trials for the Treatment of Schizophrenia (2008) (87)
- Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study (2013) (87)
- Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia (2010) (87)
- Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. (2015) (87)
- Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. (2003) (86)
- The genetics of symptom-based phenotypes: toward a molecular classification of schizophrenia. (2008) (85)
- Remission and cognitive ability in a cohort of patients with schizophrenia. (2006) (85)
- Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). (2011) (84)
- Methodological Gaps in Predicting Mental Health States from Social Media: Triangulating Diagnostic Signals (2019) (83)
- DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. (2010) (83)
- Disrupted in Schizophrenia 1 Genotype and Positive Symptoms in Schizophrenia (2007) (82)
- Antipsychotic polypharmacy: A survey study of prescriber attitudes, knowledge and behavior (2011) (82)
- Methylphenidate challenge as a predictor of relapse in schizophrenia. (1984) (81)
- Do clozapine and risperidone affect social competence and problem solving? (2004) (80)
- Medical complications of new antipsychotic drugs. (1996) (78)
- Long‐term effectiveness of oral second‐generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta‐analysis of direct head‐to‐head comparisons (2019) (78)
- 2,4-Dihydro-3H-1,2,4-triazol-3-ones as anticonvulsant agents. (1990) (78)
- Predicting Symptom Trajectories of Schizophrenia using Mobile Sensing (2017) (78)
- One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. (2007) (76)
- Treatment of schizophrenia (1995) (76)
- Consensus statement on the use of clozapine during the COVID-19 pandemic (2020) (75)
- A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. (2011) (75)
- Digital Parent Training for Children with Disruptive Behaviors: Systematic Review and Meta-Analysis of Randomized Trials. (2016) (75)
- Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. (2015) (74)
- A Prospective Study of Tardive Dyskinesia Development: Preliminary Results (1982) (73)
- Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia. (2016) (73)
- Depot neuroleptics: a comparative review of standard, intermediate, and low-dose regimens. (1986) (73)
- Diabetes and development of tardive dyskinesia. (1993) (72)
- Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial. (2020) (71)
- Sudden unexpected death in schizophrenia: Autopsy findings in psychiatric inpatients (2014) (71)
- Examining Predictors of Real-World User Engagement with Self-Guided eHealth Interventions: Analysis of Mobile Apps and Websites Using a Novel Dataset (2018) (71)
- Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it? (2012) (70)
- Do Negative Symptoms Respond to Pharmacological Treatment? (1989) (69)
- Metabolic effects of treatment with atypical antipsychotics. (2004) (69)
- Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia (2009) (69)
- Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies. (2019) (69)
- Confirmation bias: why psychiatrists stick to wrong preliminary diagnoses (2011) (69)
- Treatment-resistant schizophrenia patients (1996) (69)
- Divalproex ER Combined with Olanzapine or Risperidone for Treatment of Acute Exacerbations of Schizophrenia (2009) (68)
- First experience with a wireless system incorporating physiologic assessments and direct confirmation of digital tablet ingestions in ambulatory patients with schizophrenia or bipolar disorder. (2013) (68)
- A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. (2002) (68)
- Effect of abrupt change from standard to low serum levels of lithium: a reanalysis of double-blind lithium maintenance data. (2002) (67)
- Measurement-based psychiatry: definitions of response, remission, stability, and relapse in schizophrenia. (2006) (66)
- Implication of a rare deletion at distal 16p11.2 in schizophrenia. (2013) (66)
- Cost of antipsychotic polypharmacy in the treatment of schizophrenia (2008) (66)
- Linguistic Markers Indicating Therapeutic Outcomes of Social Media Disclosures of Schizophrenia (2017) (66)
- Methylphenidate Response, Psychopathology and Tardive Dyskinesia as Predictors of Relapse in Schizophrenia (1994) (66)
- Dexamethasone suppression tests in patients with panic disorder. (1983) (66)
- Supported employment and education in comprehensive, integrated care for first episode psychosis: Effects on work, school, and disability income (2017) (66)
- Neuropsychological Test Performance to Enhance Identification of Subjects at Clinical High Risk for Psychosis and to Be Most Promising for Predictive Algorithms for Conversion to Psychosis: A Meta-Analysis. (2017) (65)
- Risperidone: efficacy and safety. (1995) (64)
- The heterogeneity of antipsychotic response in the treatment of schizophrenia (2010) (64)
- Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics (1996) (64)
- Predictors of response to clozapine. (1994) (64)
- Sudden deaths in psychiatric patients. (2011) (63)
- Management strategies for the treatment of schizophrenia. (1999) (63)
- Prevalence of tardive dyskinesia in elderly samples. (1984) (63)
- Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. (2002) (63)
- Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. (1994) (62)
- Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis (2011) (62)
- Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis. (2015) (61)
- Transforming the Treatment of Schizophrenia in the United States: The RAISE Initiative. (2018) (61)
- Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia. (2012) (61)
- Serum lithium levels and psychosocial function in patients with bipolar I disorder. (1996) (60)
- Predictors of remission, schizophrenia, and bipolar disorder in adolescents with brief psychotic disorder or psychotic disorder not otherwise specified considered at very high risk for schizophrenia. (2008) (60)
- Real‐world effectiveness of clozapine in patients with bipolar disorder: results from a 2‐year mirror‐image study (2012) (59)
- Towards More Effective Antipsychotic Treatment (1994) (59)
- The effects of clozapine and risperidone on spatial working memory in schizophrenia. (2005) (59)
- ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial (2016) (59)
- Cerebral morphometry and clozapine treatment in schizophrenia. (1994) (58)
- An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. (2021) (58)
- A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients (2019) (57)
- Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia (2006) (57)
- Duration of untreated psychosis and time to treatment response for delusions and hallucinations. (2005) (57)
- Demographic and clinical correlates of substance use disorders in first episode psychosis (2017) (57)
- Detecting relapse in youth with psychotic disorders utilizing patient-generated and patient-contributed digital data from Facebook (2019) (57)
- Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia (2009) (56)
- Digital Peer-Support Platform (7Cups) as an Adjunct Treatment for Women With Postpartum Depression: Feasibility, Acceptability, and Preliminary Efficacy Study (2018) (56)
- Tardive dyskinesia circa 2006. (2006) (56)
- Compliance in the long-term treatment of schizophrenia. (1985) (56)
- High-dose versus low-dose strategies in the treatment of schizophrenia. (1985) (55)
- Atypical antipsychotics: sedation versus efficacy. (2008) (54)
- Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia (2016) (54)
- Relationship between Duration of Untreated Psychosis and Intrinsic Corticostriatal Connectivity in Patients with Early Phase Schizophrenia (2017) (53)
- Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. (2009) (53)
- Clozapine as a first treatment for schizophrenia. (2003) (53)
- Relationships between smartphone social behavior and relapse in schizophrenia: A preliminary report (2019) (53)
- The Role of Clozapine in Treatment-Resistant Schizophrenia. (2016) (53)
- A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. (2014) (53)
- Genomics and the future of pharmacotherapy in psychiatry (2007) (53)
- Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment. (2017) (52)
- Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia (2013) (52)
- Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months? (2011) (52)
- Predicting antipsychotic drug response – Replication and extension to six weeks in an international olanzapine study (2008) (52)
- Controlled, Double-blind Investigation of the Clozapine Discontinuation Symptoms With Conversion to Either Olanzapine or Placebo (1999) (51)
- Analyzing mHealth Engagement: Joint Models for Intensively Collected User Engagement Data (2017) (51)
- Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials (2010) (51)
- An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. (2003) (51)
- Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study. (2008) (50)
- Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia (2018) (50)
- Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance (2015) (49)
- Implications for health and disease in the genetic signature of the Ashkenazi Jewish population (2012) (49)
- A selective review of biological markers in schizophrenia. (1991) (49)
- Adverse effects of psychotropic drugs (1992) (48)
- Serotonin modulation of cerebral glucose metabolism measured with positron emission tomography (PET) in human subjects (2002) (48)
- Treatment programme and long‐term outcome in chronic schizophrenia (1990) (48)
- Chronic restlessness with antipsychotics. (2007) (48)
- A 28-WEEK, RANDOMIZED, DOUBLE-BLIND STUDY OF OLANZAPINE VERSUS ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA (2008) (48)
- Mental Health Care Providers' Attitudes Toward Telepsychiatry: A Systemwide, Multisite Survey During the COVID-19 Pandemic. (2021) (48)
- 5-Aryl-3-(alkylthio)-4H-1,2,4-triazoles as selective antagonists of strychnine-induced convulsions and potential antispastic agents. (1994) (48)
- Optimizing Treatment Choices to Improve Adherence and Outcomes in Schizophrenia. (2019) (47)
- Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System (2020) (46)
- Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. (2006) (46)
- Efficacy and Safety of Lumateperone for Treatment of Schizophrenia (2020) (46)
- Rapid clozapine titration in treatment-refractory bipolar disorder. (2014) (46)
- Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia (2013) (45)
- Evaluation of Differences in Individual Treatment Response in Schizophrenia Spectrum Disorders: A Meta-analysis. (2019) (45)
- The dexamethasone suppression test in depression. (1983) (45)
- Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. (2010) (45)
- Incidence of Tardive Dyskinesia with Risperidone or Olanzapine in the Elderly: Results from a 2-Year, Prospective Study in Antipsychotic-Naïve Patients (2011) (45)
- Tardive dyskinesia induced by risperidone? (1996) (44)
- Cognitive impairment in tardive dyskinesia (1985) (44)
- Is there a trial bias impacting user engagement with unguided e-mental health interventions? A systematic comparison of published reports and real-world usage of the same programs. (2019) (44)
- Changes in telepsychiatry regulations during the COVID-19 pandemic: 17 countries and regions' approaches to an evolving healthcare landscape (2020) (44)
- Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives (2011) (43)
- Patterns of stress in schizophrenia (2008) (43)
- Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders. (2015) (43)
- T204. CLOZAPINE COMBINATION AND AUGMENTATION STRATEGIES IN PATIENTS WITH SCHIZOPHRENIA –RECOMMENDATIONS FROM AN INTERNATIONAL EXPERT SURVEY AMONG THE TREATMENT RESPONSE AND RESISTANCE IN PSYCHOSIS (TRRIP) WORKING GROUP (2020) (43)
- Adjunctive antipsychotic treatment is necessary for adolescents with psychotic mania. (2001) (43)
- Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies (2016) (43)
- Effectiveness and safety of rapid clozapine titration in schizophrenia (2014) (42)
- Do Asian Patients Require Only Half of the Clozapine Dose Prescribed for Caucasians? A Critical Overview (2020) (42)
- Problems of compliance in the outpatient treatment of schizophrenia. (1983) (42)
- Haloperidol versus chlorpromazine for schizophrenia. (2008) (42)
- The Use of Higher-Dose Antipsychotic Medication (1994) (42)
- Low dose fluphenazine decanoate in maintenance treatment of schizophrenia (1979) (42)
- Antidepressants for cognitive impairment in schizophrenia — A systematic review and meta-analysis (2014) (42)
- Completed and attempted suicides among 18,154 subjects with schizophrenia included in a large simple trial. (2014) (42)
- Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes. (2009) (41)
- A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. (2011) (41)
- Guidelines for Neuroleptic Relapse Prevention in Schizophrenia: Towards a Consensus View (1991) (41)
- Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. (2020) (41)
- Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies (2017) (41)
- Characterizing Audience Engagement and Assessing Its Impact on Social Media Disclosures of Mental Illnesses (2018) (41)
- Low-dose neuroleptic treatment of outpatient schizophrenics: preliminary results for relapse rates (1984) (40)
- Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis (2015) (40)
- Clozapine effects on tardive dyskinesia. (1989) (40)
- Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. (2020) (40)
- Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks (2007) (40)
- Association of genetic variation in the MET proto-oncogene with schizophrenia and general cognitive ability. (2010) (40)
- Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials (2018) (39)
- A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers (2017) (39)
- Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials. (2016) (38)
- Body mass index identified as an independent predictor of psychiatric readmission. (2014) (38)
- The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics. (2008) (38)
- Ziprasidone and the Corrected QT Interval (2012) (38)
- Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia (2013) (37)
- Improving patient outcomes in schizophrenia: achieving remission, preventing relapse, and measuring success. (2013) (37)
- Consensus statement on the use of clozapine during the COVID-19 pandemic. (2020) (37)
- Factors which can make Patients Difficult to Treat (1996) (36)
- Guidelines for the use of long-acting injectable atypical antipsychotics (2004) (36)
- Treatment of tardive dyskinesia with bromocriptine. A test of the receptor modification strategy. (1989) (36)
- Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). (2006) (36)
- Telepsychiatry Education and Curriculum Development in Residency Training (2015) (36)
- Utilization of Long-Acting Antipsychotic Medication in Patient Care (2006) (36)
- A short synthesis of the parp inhibitor 2-(4-trifluoro-methylphenyl)benzimidazole-4-carboxamide (NU1077) (2001) (36)
- Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention. (2017) (35)
- Clozapine, negative symptoms, and extrapyramidal side effects. (1994) (35)
- The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients. (2004) (35)
- Left middle temporal gyrus activation during a phonemic discrimination task (2004) (35)
- Predicting Early Warning Signs of Psychotic Relapse From Passive Sensing Data: An Approach Using Encoder-Decoder Neural Networks (2020) (35)
- Clozapine: Plasma levels and prolactin response (2004) (34)
- Pharmacologic characterization of tardive dyskinesia. (1988) (34)
- Pharmacoepidemiology of Antipsychotic Use in Youth with ADHD: Trends and Clinical Implications (2013) (34)
- Safety and efficacy of bupropion in elderly patients: preliminary observations. (1983) (34)
- Dexamethasone suppression tests in patients with obsessive-compulsive disorder. (1985) (34)
- Benign Ethnic Neutropenia and Clozapine Use: A Systematic Review of the Evidence and Treatment Recommendations. (2016) (34)
- THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY SURVEY OF PSYCHOPHARMACOLOGISTS’ PRACTICE PATTERNS FOR THE TREATMENT OF MOOD DISORDERS (2015) (33)
- Strategy for the study of patients at high risk for tardive dyskinesia. (1980) (33)
- Psychological well-being and mental health recovery in the NIMH RAISE early treatment program (2017) (33)
- Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects. (1993) (33)
- Patterns and predictors of medication discrepancies in primary care. (2015) (32)
- Plasma levels of second-generation antipsychotics and clinical response in acute psychosis: A review of the literature (2013) (32)
- Epidemiology of Tardive Dyskinesia (1983) (32)
- Sedation as a side effect of the treatment of mental disorders. (2008) (31)
- Technology-Assisted Parent Training Programs for Children and Adolescents With Disruptive Behaviors: A Systematic Review. (2017) (31)
- Obesity and coronary risk in patients treated with second-generation antipsychotics (2011) (31)
- Low dose medication strategies in the maintenance treatment of schizophrenia. (1983) (31)
- Lead-Time Bias Confounds Association Between Duration of Untreated Psychosis and Illness Course in Schizophrenia. (2020) (30)
- Unanswered questions in schizophrenia clinical trials. (2007) (30)
- Cortisol levels in relation to hippocampal sub-regions in subjects with first episode schizophrenia (2007) (30)
- Prevalence of abnormal involuntary movements (“spontaneous dyskinesias”) in the normal elderly (2004) (30)
- Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis (2016) (30)
- Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes (2011) (30)
- Use of Remote Centralized Raters Via Live 2-Way Video in a Multicenter Clinical Trial for Schizophrenia (2008) (30)
- Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial. (2019) (30)
- F120. USING DIGITAL MEDIA ADVERTISING IN EARLY PSYCHOSIS INTERVENTION (2017) (29)
- Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. (2015) (29)
- Adjunctive armodafinil for negative symptoms in adults with schizophrenia: A double-blind, placebo-controlled study (2012) (29)
- Tools to assess negative symptoms in schizophrenia. (2013) (29)
- Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit (2020) (29)
- A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. (2009) (29)
- Prospective Relationships Between Motivation and Functioning in Recovery After a First Episode of Schizophrenia (2018) (29)
- Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics. (2013) (29)
- Improving treatment adherence in patients with schizophrenia. (2011) (29)
- Antipsychotic polypharmacy: A Japanese survey of prescribers' attitudes and rationales (2013) (28)
- The importance of cross-sectional remission in schizophrenia for long-term outcome: A clinical prospective study (2009) (28)
- The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and A Roadmap for Future Research. (2020) (27)
- Impact of online resources and social media on help‐seeking behaviour in youth with psychotic symptoms (2016) (27)
- Antipsychotic drug administration does not correlate with prolonged rate-corrected QT interval in children and adolescents: results from a nested case-control study. (2011) (27)
- Revisiting the Abnormal Involuntary Movement Scale: Proceedings From the Tardive Dyskinesia Assessment Workshop. (2018) (27)
- Addressing nonresponse in schizophrenia. (2012) (27)
- Pharmacologic studies of tardive dyskinesia. (1988) (26)
- Patient Attitudes Toward Telepsychiatry During the COVID-19 Pandemic: A Nationwide, Multisite Survey (2020) (26)
- Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials (2016) (26)
- Biological treatment of acute agitation or aggression with schizophrenia or bipolar disorder in the inpatient setting. (2017) (26)
- The FEZ1 Gene Shows No Association to Schizophrenia in Caucasian or African American Populations (2007) (26)
- Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study. (2016) (25)
- Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis (2016) (25)
- Neuromuscular effects of monoamine oxidase inhibitors. (1985) (25)
- Tardive Dyskinesia Among Chinese and Malay Patients With Schizophrenia (2002) (25)
- The QTc interval and its dispersion in patients receiving two atypical antipsychotics (2009) (25)
- Accuracy of Clinician Assessments of Medication Status in the Emergency Setting: A Comparison of Clinician Assessment of Antipsychotic Usage and Plasma Level Determination (2017) (25)
- There is a non-evidence-based app for that: A systematic review and mixed methods analysis of depression- and anxiety-related apps that incorporate unrecognized techniques. (2020) (24)
- Prevention and Treatment of Neuroleptic Noncompliance (1986) (24)
- BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: A meta-analysis (2014) (24)
- Patients' Attitudes Towards Telepsychiatry: Results of a Nationwide, Multisite Survey During the COVID-19 Pandemic. (2020) (24)
- Pyrrolo[1,2-c]thiazole, a ring-fused nonclassical thiazole system (1980) (24)
- Predictors of suicide attempts in 3.322 patients with affective disorders and schizophrenia spectrum disorders (2015) (24)
- Familial occurrence of tardive dyskinesia. (1981) (24)
- Relationship between the B-mitten EEG pattern and tardive dyskinesia. A pilot control study. (1979) (24)
- QT interval duration and dispersion in children and adolescents treated with ziprasidone. (2011) (24)
- Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia (2010) (24)
- Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study (2020) (23)
- Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone (2013) (23)
- Akathisia and clozapine treatment. (1993) (23)
- Brainstem Frequency-Following Responses and Cortical Event-Related Potentials during Attention (1993) (23)
- Implementation and fidelity assessment of the NAVIGATE treatment program for first episode psychosis in a multi-site study (2019) (23)
- An evidence-based strategy for remission in schizophrenia. (2008) (23)
- Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia (2019) (23)
- Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1 (2018) (23)
- Digital Trajectories to Care in First-Episode Psychosis. (2018) (23)
- Clinical guidelines: Dosing and switching strategies for long-acting risperidone. (2003) (23)
- The effect of marijuana use on the risk for schizophrenia. (2012) (22)
- COMT genotype and manic symptoms in schizophrenia (2006) (22)
- Treatment models and designs for intervention research during the psychotic prodrome. (2003) (22)
- The dopamine-serotonin relationship in clozapine response (1993) (22)
- Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. (2017) (22)
- Sertindole (Serdolect): preclinical and clinical findings of a new atypical antipsychotic. (1997) (22)
- Home-Based Outpatient Telepsychiatry to Improve Adherence With Treatment Appointments: A Pilot Study. (2017) (22)
- Frequency and correlates of DSM-5 attenuated psychosis syndrome in a sample of adolescent inpatients with nonpsychotic psychiatric disorders. (2015) (22)
- Pharmacologic treatment of schizophrenia (1999) (22)
- Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials. (2009) (21)
- Using behavioral rhythms and multi-task learning to predict fine-grained symptoms of schizophrenia (2020) (21)
- MDL 26,479: a potential cognition enhancer with benzodiazepine inverse agonist‐like properties (1992) (21)
- Effects of aripiprazole once-monthly on domains of personal and social performance: Results from 2 multicenter, randomized, double-blind studies (2014) (21)
- Identifying signals associated with psychiatric illness utilizing language and images posted to Facebook (2020) (21)
- Coordinated Technology-Delivered Treatment to Prevent Rehospitalization in Schizophrenia: A Novel Model of Care. (2016) (21)
- Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group. (1999) (21)
- I: Relapse Rates After 1 Year (1986) (21)
- Clozapine pharmacology and tardive dyskinesia (2004) (21)
- The use of clozapine in neurologic disorders. (1994) (21)
- Off-hours use of a smartphone intervention to extend support for individuals with schizophrenia spectrum disorders recently discharged from a psychiatric hospital (2019) (21)
- Subcortical modulation of attentional control by second-generation antipsychotics in first-episode psychosis (2014) (21)
- Social Sensing: Assessing Social Functioning of Patients Living with Schizophrenia using Mobile Phone Sensing (2020) (21)
- The role of neuroleptics in manic-depressive illness. (1988) (20)
- Demographic, psychosocial, clinical, and neurocognitive baseline characteristics of Black Americans in the RAISE-ETP study (2017) (20)
- Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate. (1986) (20)
- Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia (2011) (20)
- Smartphone relapse prediction in serious mental illness: a pathway towards personalized preventive care (2020) (20)
- Objective identification and analysis of physiological and behavioral signs of schizophrenia (2015) (20)
- Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study (2019) (19)
- Creating a health care team to manage chronic medical illnesses in patients with severe mental illness: the public policy perspective. (2009) (19)
- Incomes and Outcomes: Social Security Disability Benefits in First-Episode Psychosis. (2017) (19)
- Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness. (2007) (19)
- Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study. (2021) (19)
- Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2 (2018) (19)
- Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder. (2017) (19)
- Analysis of TBX1 Variation in Patients with Psychotic and Affective Disorders (2007) (19)
- Cognitive deficits in schizophrenia: short‐term and long‐term (2008) (19)
- Recent Advances in the Synthesis of Piperidones and Piperidines (2003) (18)
- Predictive value of eosinophilia for neutropenia during clozapine treatment. (1996) (18)
- Addressing side effects from antipsychotic treatment in schizophrenia. (2011) (18)
- Health Technology Intervention After Hospitalization for Schizophrenia: Service Utilization and User Satisfaction. (2016) (18)
- Prediction of relapse in schizophrenia. (1986) (18)
- Capturing behavioral indicators of persecutory ideation using mobile technology. (2019) (18)
- Tardive dyskinesias and drugs (1986) (18)
- Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference (2019) (18)
- Correlates of substance misuse in patients with first‐episode schizophrenia and schizoaffective disorder (2001) (18)
- Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review (2020) (17)
- Efficacy and tolerability of clozapine in Japanese patients with treatment-resistant schizophrenia: results from a 12-week, flexible dose study using raters masked to antipsychotic choice. (2013) (17)
- Low-density lipoprotein cholesterol in patients treated with atypical antipsychotics: Missed targets and lost opportunities (2007) (17)
- Neuroleptic-Induced Movement Disorders: Aging and tardive dyskinesia (1996) (17)
- Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo (2000) (17)
- Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia (2011) (17)
- MDL 27,531 selectively reverses strychnine‐induced seizures in mice (1992) (17)
- Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia: A Randomized Clinical Trial. (2019) (17)
- Methylphenidate challenge tests and course of schizophrenia. (1985) (17)
- Lurasidone: a clinical overview. (2011) (17)
- Ziprasidone-induced cognitive enhancement in schizophrenia: Specificity or pseudospecificity? (2006) (17)
- Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial (2015) (16)
- Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: Findings of the three national surveys on use of psychotropic medications in China (2002–2012) (2015) (16)
- Experience of quality of life and attitude to care and treatment in patients with schizophrenia: Role of cross-sectional remission (2008) (16)
- Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential. (1993) (16)
- Suicidality and hospitalization as cause and outcome of pediatric psychiatric emergency room visits (2015) (16)
- Continuous assessment of schizophrenia using heart rate and accelerometer data (2017) (16)
- Psychopharmacological screening criteria. APA Committee on Research on Psychiatric Treatments. (1992) (16)
- Predictors of Hospitalization of Individuals With First-Episode Psychosis: Data From a 2-Year Follow-Up of the RAISE-ETP. (2019) (16)
- Neuroleptic treatment of elderly patients. (1995) (16)
- Enhancement of working memory performance in the rat by MDL 26,479, a novel compound with activity at the GABAA receptor complex (1992) (15)
- Current problems with the pharmacotherapy of schizophrenia (1995) (15)
- Online help-seeking prior to diagnosis: Can web-based resources reduce the duration of untreated mood disorders in young people? (2019) (15)
- Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth. (2013) (15)
- Effectiveness of a Cognitive Behavioral Weight Management Intervention in Obese Patients With Psychotic Disorders Compared to Patients With Nonpsychotic Disorders or No Psychiatric Disorders: Results From a 12-month, Real-World Study (2012) (15)
- The future of pharmacotherapy for schizophrenia. (2003) (15)
- A systematic review and pooled, patient‐level analysis of predictors of mortality in neuroleptic malignant syndrome (2021) (15)
- Long-acting injectable risperidone: Efficacy and safety (2002) (15)
- Assessing the relationship between routine and schizophrenia symptoms with passively sensed measures of behavioral stability (2020) (15)
- Dose and safety concerns of clozapine: Worldwide package inserts need revisions (2020) (15)
- Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia (2021) (15)
- Structural similarity networks predict clinical outcome in early-phase psychosis (2019) (15)
- The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents (2023) (15)
- Using therapeutic drug monitoring to personalize clozapine dosing in Asians (2020) (15)
- Olanzapine (Zyprexa):characteristics of a new antipsychotic. (1997) (14)
- Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation (2020) (14)
- The bis(tricyclohexylstannyl) sulfide thionation of 3H-1,2,4-triazol-3-ones (1987) (14)
- ANTIBODIES TO ACETYLCHOLINE RECEPTORS IN TARDIVE DYSKINESIA (1984) (14)
- Ranking Antipsychotics for Efficacy and Safety in Schizophrenia. (2020) (14)
- Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort. (2021) (14)
- Clinically Significant Drug–Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder (2019) (14)
- Medical outcome of psychiatric inpatients with admission hyponatremia (2012) (14)
- Predicting relapse in schizophrenia: Is BDNF a plausible biological marker? (2017) (14)
- Preclinical characterization of MDL 27,192 as a potential broad spectrum anticonvulsant agent with neuroprotective properties (1997) (14)
- Antipsychotic drug side effects: their relationship to dose. (1985) (14)
- An extremely short synthesis of benzoylpyrrole-type calcium channel activators (1992) (13)
- The New Antipsychotics (1997) (13)
- The efficacy of amoxapine, maprotiline, and trazodone in comparison to imipramine and amitriptyline: a review of the literature. (1984) (13)
- Optimizing pharmacotherapy to maximize outcome in schizophrenia. (2005) (13)
- Serotonin in Antipsychotic Treatment: Mechanisms and Clinical Practice (1996) (13)
- High plasma clozapine levels in tardive dyskinesia. (1993) (13)
- The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: A pooled analysis of data from the pivotal trials (2008) (13)
- Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: A randomized, double-blind, active parallel-controlled, multicenter clinical trial (2014) (13)
- Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies (2011) (13)
- Efficacy of clozapine versus haloperidol in a long-term clinical trial (1996) (13)
- Clozapine and akathisia (1992) (13)
- The role of NMDA receptors in schizophrenia. (2015) (13)
- Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials. (2003) (13)
- Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients. (1994) (13)
- Psychosis breakthrough on antipsychotic maintenance medication (BAMM): what can we learn? (2017) (13)
- A one-year comparison of four dosages of haloperidol decanoate (1993) (13)
- Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of Schizophrenia. (2009) (13)
- Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic Review (2016) (13)
- Synthesis and sar of 4-(1H-benzimidazole-2-carbonyl)piperidines with dual histamine H1/tachykinin NK1 receptor antagonist activity (1997) (12)
- Synthesis of FPL 64176 by 1,3-Dipolar Cycloaddition (1995) (12)
- Indications for and use of long-acting injectable antipsychotics: consideration from an inpatient setting (2017) (12)
- Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data. (2021) (12)
- The use of depot neuroleptics: clinical experience in the United States. (1984) (12)
- Comparative utility of aripiprazole and haloperidol in schizophrenia (2012) (12)
- Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies. (2015) (12)
- Commentaries on the Schizophrenia Patient Outcomes Research Team (PORT) Studies (1998) (12)
- The reactions of thiosemicarbazides and 5-halovalerophenones (1988) (12)
- Perceived Autonomy Support in the NIMH RAISE Early Treatment Program. (2017) (11)
- Guidelines for biological Treatment of Schizophrenia, : Part 1: Acute Treatment of Schizophrenia and Part 2: Long-term Treatment of Schizophrenia (2005) (11)
- Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation (2015) (11)
- Schizophrenia: mechanism of action of current and novel treatments. (2014) (11)
- Epidemiological aspects of tardive dyskinesia. (1988) (11)
- Use of Behavioral Economics to Improve Medication Adherence in Severe Mental Illness. (2019) (11)
- Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison. (2016) (11)
- The prevalence of tardive dyskinesia. (1985) (11)
- Is Transcultural Psychiatry Possible? (2019) (11)
- Predicting a ‘Combined Treatment Outcome’ in Chronic Schizophrenia: The Role of Demographics, Symptomatology, Functioning and Subjective Well-being (2013) (11)
- Dosage and Route of Administration of Neuroleptic Drugs During Different Phases of a Schizophrenic Illness (1991) (11)
- Attitudinal barriers to prescribing LAI antipsychotics in the outpatient setting: communicating with patients, families, and caregivers. (2014) (11)
- Polydipsia and tardive dyskinesia in chronic psychiatric patients--related disorders? (1993) (11)
- Akathisia and clozapine treatment (1993) (11)
- What Makes an Antipsychotic ‘Atypical’? (1997) (11)
- Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review (2021) (10)
- A highly convergent synthesis of benzimidazolylpiperidines (1990) (10)
- Technology-based interventions in health care (2014) (10)
- The Relationship Between Acoustic Startle Response Measures and Cognitive Functions in Japanese Patients with Schizophrenia (2012) (10)
- Unravelling cases of clozapine-related Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in patients reported otherwise: A systematic review (2021) (10)
- A New Treatment Paradigm (2022) (10)
- Genome-wide association study implicates NDST 3 in schizophrenia and bipolar disorder (2013) (10)
- On Predicting Relapse in Schizophrenia using Mobile Sensing in a Randomized Control Trial (2020) (10)
- Responses to Tobacco Smoking-Related Health Messages in Young People With Recent-Onset Schizophrenia. (2015) (10)
- Sertindole: a review of clinical efficacy (1998) (10)
- Discovery of Genetic Markers Associated with Clozapine Induced Agranulocytosis. (2005) (10)
- What can we achieve by implementing a compliance‐improvement program? (1997) (10)
- Haloperidol versus chlorpromazine for treatment of schizophrenia. (2008) (10)
- Risk factors for medical deterioration of psychiatric inpatients: opportunities for early recognition and prevention. (2012) (10)
- Prevalence of impaired kidney function in patients with long‐term lithium treatment: A systematic review and meta‐analysis (2021) (10)
- Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy (2011) (10)
- Predictors of relapse in schizophrenia (1986) (10)
- Abnormal Resting State fMRI Activity Predicts Processing Speed Deficits in First-Episode Psychosis (2015) (10)
- Predictors of aggression in 3.322 patients with affective disorders and schizophrenia spectrum disorders evaluated in an emergency department setting (2017) (10)
- Can schizophrenia with premorbid asociality be genetically distinguished from the other forms of schizophrenia? (1980) (10)
- A 6-week Randomized, Double-blind, Placebo-controlled, Comparator Referenced, Multicenter Trial of Vabicaserin in Subjects With Acute Exacerbation of Schizophrenia (2011) (10)
- ω-3 Polyunsaturated Fatty Acids to Prevent Psychosis: The Importance of Replication Studies. (2017) (10)
- Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study. (2015) (9)
- Does using marijuana increase the risk for developing schizophrenia? (2013) (9)
- Outcomes of Neuroleptic Malignant Syndrome With Depot Versus Oral Antipsychotics: A Systematic Review and Pooled, Patient-Level Analysis of 662 Case Reports. (2020) (9)
- P0261 - Comparative mortality associated with ziprasidone vs. olanzapine in real-world use: The ziprasidone observational study of cardiac outcomes (zodiac) (2008) (9)
- Attitudes of patients and family members towards implantable psychiatric medication (2008) (9)
- Guidelines for the use of long-acting injectable atypical antipsychotics (2004) (9)
- The B-mitten EEG pattern and tardive dyskinesia: a possible association. (1977) (9)
- Utilizing Machine Learning on Internet Search Activity to Support the Diagnostic Process and Relapse Detection in Young Individuals With Early Psychosis: Feasibility Study (2020) (9)
- Treatment, services, and environmental factors. (1988) (9)
- An unusual cleavage of 2,5-difluorobenzophenone (1986) (9)
- Obstacles to clinical research and new drug development in schizophrenia. (1991) (9)
- Low Incidence of Neuroleptic Malignant Syndrome Associated With Paliperidone Palmitate Long-Acting Injectable (2019) (9)
- Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study. (2016) (9)
- Recommendations for the monitoring of serum concentrations of antipsychotic drugs in the treatment of schizophrenia. (2015) (9)
- LOW FREQUENCY OF TARDIVE DYSKINESIA IN ELDERLY PATIENTS WITH DEMENTIA EXPOSED TO RISPERIDONE FOR UP TO ONE YEAR (1999) (9)
- Focused Ethnographic Examination of Barriers to Use of Long-Acting Injectable Antipsychotics. (2019) (9)
- Lessons learned in the conduct of a global, large simple trial of treatments indicated for schizophrenia. (2013) (9)
- Google search activity in early psychosis: A qualitative analysis of internet search query content in first episode psychosis (2020) (8)
- Patterns of clozapine and other antipsychotics prescriptions in patients with treatment-resistant schizophrenia in community mental health centers in São Paulo, Brazil (2015) (8)
- Adding Oral Contraceptives to Clozapine May Require Halving the Clozapine Dose: A New Case and a Literature Review. (2020) (8)
- Longitudinal associations of family burden and patient quality of life in the context of first-episode schizophrenia in the RAISE-ETP study (2019) (8)
- Clozapine is underutilized (2012) (8)
- Antipsychotic polypharmacy in the treatment of schizophrenia (2003) (8)
- Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia (2017) (8)
- Effect of daily dose of chronic haloperidol and chronic apomorphine on behavioral hypersensitivity in the rat (2004) (8)
- Medication Prescription Practices for the Treatment of First Episode Schizophrenia-Spectrum Disorders: Data from the National RAISE-ETP Study (2015) (8)
- Alkylation of protected piperazinone dianions (1980) (8)
- OLANZAPINE LONG-ACTING INJECTION FOR THE MAINTENANCE TREATMENT OF SCHIZOPHRENIA: A 24-WEEK, RANDOMIZED, DOUBLE-BLIND TRIAL (2008) (8)
- [Clozapine in the treatment of schizophrenia]. (1991) (8)
- 532 Predictors of response to clozapine in a long-term double blind treatment study (1997) (8)
- Summary of Key Issues Raised in the Technology for Early Awareness of Addiction and Mental Illness (TEAAM-I) Meeting. (2018) (8)
- Serotonin 6 receptor gene and schizophrenia: case‐control study and meta‐analysis (2012) (8)
- The field of schizophrenia: strengths, weaknesses, opportunities, and threats. (2012) (8)
- The synthesis of 3H-1,2,4-thiadiazolo[3,4-b]benzothiazoles† (1989) (8)
- PREDICTING SYMPTOM TRAJECTORIES OF SCHIZOPHRENIA USING MOBILE SENSING (2018) (8)
- Clozapine administration in clinical practice: once‐daily versus divided dosing (2016) (8)
- Difference in catalepsy response in inbred rats during chronic haloperidol treatment is not predictive of the intensity of behavioral hypersensitivity which subsequently develops (2004) (8)
- Haloperidol and sudden cardiac death in dementia: autopsy findings in psychiatric inpatients (2015) (8)
- Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials (2021) (8)
- Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial (2022) (8)
- ANTIPSYCHOTIC COMBINATIONS VERSUS MONOTHERAPY IN SCHIZOPHRENIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (2008) (8)
- IMPROVING OUTCOMES OF FIRST-EPISODE PSYCHOSIS (2017) (7)
- The effects of a potential antidepressant, 2,4-dimethyl-5-(3-fluorophenyl)-3h-1,2,4-triazole-3-thione, in an electrophysiological model responsive to desipramine (1990) (7)
- Factor structure of therapist fidelity to individual resiliency training in the Recovery After an Initial Schizophrenia Episode Early Treatment Program (2018) (7)
- 2,4‐Dihydro‐3H‐1,2,4‐triazol‐3‐ones as Anticonvulsant Agents. (1991) (7)
- Metabolic risks and effects of atypical antipsychotic treatment. (2007) (7)
- Iron homeostasis alterations and risk for akathisia in patients treated with antipsychotics: A systematic review and meta-analysis of cross-sectional studies (2020) (7)
- The reaction of 4‐alkyl‐3‐thiosemicarbazides with β‐haloketones (1983) (7)
- Strategies for making an accurate differential diagnosis of schizoaffective disorder. (2010) (7)
- Progress toward the total synthesis of maytansinoids. A facile route to the aromatic moiety (western zone) (1977) (7)
- Screening the European pharmacovigilance database for reports of clozapine-related DRESS syndrome: 47 novel cases (2022) (7)
- Identification of high-risk coronary heart disease patients receiving atypical antipsychotics: single low-density lipoprotein cholesterol threshold or complex national standard? (2008) (7)
- Dosing issues and depot medication in the maintenance treatment of schizophrenia. (1995) (7)
- Development and Validation of a Computerized Adaptive Assessment Tool for Discrimination and Measurement of Psychotic Symptoms. (2020) (7)
- Follow-up study on the reversibility of tardive dyskinesia. (1982) (7)
- Improvement or relief from side effects. (1977) (7)
- Optimizing pharmacologic treatment of psychotic disorders. Commentary (2003) (7)
- Suicide in a psychiatric population. (1982) (6)
- Psychotropic Medication Use Is Associated With Greater 1-Year Incidence of Dementia After COVID-19 Hospitalization (2022) (6)
- 553 Pilot study of atypical antipsychotic agents in first episode schizophrenia (1997) (6)
- A Social Media Study on Mental Health Status Transitions Surrounding Psychiatric Hospitalizations (2021) (6)
- Medical Outcome of Patients With Dementia in a Free-Standing Psychiatric Hospital (2013) (6)
- Dose selection and comparator drugs in schizophrenia research. (2001) (6)
- Assessing negative symptoms and extrapyramidal symptoms in schizophrenia: workshop report. (1993) (6)
- Schizophrenia research: challenges and opportunities (1995) (6)
- Identifying emerging mental illness utilizing search engine activity: A feasibility study (2020) (6)
- Considerations on "organic" exclusion criteria for schizophrenia. (1991) (6)
- Predicting relapse with residual symptoms in schizophrenia: A secondary analysis of the PROACTIVE trial (2020) (6)
- Analysis of TBX 1 Variation in Patients with Psychotic and Affective Disorders (2007) (6)
- Relapse prevention in patients with schizophrenia. (2008) (6)
- Antipsychotic medication in the treatment of schizophrenia. (1995) (6)
- Efficacy and safety of a novel long-acting risperidone formulation (2002) (6)
- A convergent synthesis of 4-(2-benzothiazoyl)piperidines with antihistamic activity (1993) (6)
- Is Clozapine Response Different in Neuroleptic Nonresponders vs Partial Responders?-Reply (1990) (6)
- An Improved Method for the Synthesis of 5-Aryl-3-methyl-2-methylimino-1,3,4-Oxadiazoles (1992) (6)
- Choosing between old and new antipsychotics (1996) (6)
- Innovations in the Psychopharmacologic Treatment of Schizophrenia (1989) (6)
- P.2.105 Efficacy and safety of aripiprazole versus perphenazine in treatment-resistant schizophrenia (2003) (6)
- The impact of clozapine on psychosocial competence (1995) (6)
- P.3.c.033 Long-acting injectable vs. oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image and cohort studies (2012) (6)
- LONG-TERM TREATMENT OF SCHIZOPHRENIA: MOVING FROM A RELAPSE PREVENTION MODEL TO A RECOVERY MODEL * (2003) (6)
- Newer Antipsychotic Drugs (1993) (5)
- Adoption of Digital Health Technologies in the Practice of Behavioral Health: Qualitative Case Study of Glucose Monitoring Technology. (2021) (5)
- Clinical challenges in the psychopharmacology of schizophrenia. (1997) (5)
- Utilizing Instagram Data to Identify Usage Patterns Associated With Schizophrenia Spectrum Disorders (2021) (5)
- Clozapine and tardive dyskinesia: Prospective data (1991) (5)
- Chapter 7 - Seven-Membered Rings (1991) (5)
- Long-range fluorine-proton coupling in 1,2,4-triazole derivatives (1995) (5)
- Accounting for group differences in study retention in a randomized trial of specialized treatment for first episode psychosis (2017) (5)
- Relationship of Mitten Patterns to Neuroleptic Drug Induced Dyskinesias in Psychiatric Patients: Early Investigative Findings (1979) (5)
- Tardive Dyskinesia in the Elderly: Data From a Prospective Study (2002) (5)
- PRIMARY AND READJUDICATION MORTALITY RESULTS FROM ZODIAC, A LARGE SIMPLE TRIAL OF ZIPRASIDONE VS. OLANZAPINE IN PATIENTS WITH SCHIZOPHRENIA (2010) (5)
- Patient-Independent Schizophrenia Relapse Prediction Using Mobile Sensor Based Daily Behavioral Rhythm Changes (2021) (5)
- Incidence of tardive dyskinesia: five-year data from a prospective study. (1984) (5)
- Tardive dyskinesia and impaired glucose tolerance (2002) (5)
- The scourge of EPS: have atypical antipsychotics solved the problem? (2000) (5)
- Striatal functional connectivity in psychosis relapse: A hypothesis generating study (2021) (5)
- Clozapine conflict [6] (1996) (5)
- The Mitten pattern as a potential EEG predictor of tardive dyskinesia [proceedings]. (1978) (5)
- Use of CoMFA in validating the conformation used in designing 4-(1H-benzimidazole-2-carbonyl)piperidines with H1/NK1 receptor antagonist activity (1997) (5)
- Schizophrenia: how far have we come? (1999) (5)
- The physical health and side-effect monitoring of patients prescribed clozapine: data from a clinical audit conducted in UK mental health services (2020) (5)
- Poster #208 EFFECTIVENESS OF LURASIDONE VS. QUETIAPINE XR FOR RELAPSE PREVENTION IN SCHIZOPHRENIA: A 12-MONTH, DOUBLE-BLIND STUDY (2012) (5)
- Organizational Barriers to Using Long-Acting Injectable Antipsychotics in Practice (2014) (5)
- Choosing among old and new antipsychotics. (1996) (5)
- Development of a computerized adaptive diagnostic screening tool for psychosis (2021) (5)
- PORT recommendations. (2004) (5)
- The Cognitive Deficit subscale of the SCL-90-R and prediction of outcome in first episode schizophrenics. (1985) (5)
- Burnout and the Quantified Workplace: Tensions around Personal Sensing Interventions for Stress in Resident Physicians (2022) (4)
- CSF sub-compartments in relation to plasma osmolality in healthy controls and in patients with first episode schizophrenia (2007) (4)
- Comments on Abilify MyCite. (2018) (4)
- Neuropsychological and Electroencephalographic Correlates of Neuroleptic Induced Involuntary Movements: Implications for Tardive Dyskinesia (1982) (4)
- P.3.c.054 Results of a study on psychiatrists' perceptions of adherence to medication among patients with schizophrenia: the ADHES survey (2007) (4)
- P.671 Efficacy and safety of lumateperone tosylate 42mg in the treatment of schizophrenia: A pooled analysis of phase 2 and 3 studies (2019) (4)
- Towards a framework to develop neuroimaging biomarkers of relapse in schizophrenia (2021) (4)
- Addressing Patients' Unmet Needs to Improve Outcomes in Schizophrenia. (2021) (4)
- Preliminary findings with regard to risk factors in the development of tardive dyskinesia [proceedings]. (1981) (4)
- Treatment response and resistance in schizophrenia: principles and definitions (2018) (4)
- Clozapine Reduces All-Cause Mortality. (2017) (4)
- mHealth-Assisted Detection of Precursors to Relapse in Schizophrenia (2021) (4)
- Baseline Characteristics and Early Response at Week 1 Predict Treatment Outcome in Adolescents With Bipolar Manic or Mixed Episode Treated With Olanzapine: Results From a 3-Week, Randomized, Placebo-Controlled Trial. (2017) (4)
- Risperidone: new horizons for the schizophrenic patient. 9th World Congress of Psychiatry of the World Psychiatric Association, Rio de Janeiro, June 1993. (1994) (4)
- A Short Synthesis of the PARP Inhibitor 2‐(4‐Trifluoromethylphenyl)benzimidazole‐4‐carboxamide (NU1077) (V). (2001) (4)
- Assessing Patients for Tardive Dyskinesia. (2017) (4)
- Update on treatment strategies (1997) (4)
- Electroconvulsive Therapy Augmentation in Clozapine-Resistant Schizophrenia: A Prospective, Randomized Study. (2019) (4)
- Pharmacovigilance approaches to study rare and very rare side-effects: the example of clozapine-related DiHS/DRESS syndrome (2022) (4)
- The reaction of substituted thiosemicarbazides and γ-haloketones (1984) (4)
- The effects of the Affordable Care Act on the practice of psychiatry. (2013) (3)
- Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. (2020) (3)
- Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis. (2022) (3)
- Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia: Additional Results From the KINECT 3 Study. (2018) (3)
- Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia (2008) (3)
- The prevalence of presumed tardive dyskinesia in psychiatric inpatients and outpatients (2004) (3)
- The enhancement of muscimol-stimulated 36C1 influx by the antispastic 5-aryl-3-(alkylsulfonyl)-4H-1,2,4-triazole (MDL 27 531) in rat brain membrane vesicles (1995) (3)
- Incentivizing Is Not Coercing: A Commentary. (2020) (3)
- Clinical Challenges in the Psychopharmacology of Schizophrenia: Editors' Introduction (1997) (3)
- The enhancement and inhibition of in vivo binding of [3H]R015-1788 in mouse cerebral cortex by a series of 5-aryltriazoles (1990) (3)
- Prevalence of tardive dyskinesia in elderly samples. (1984) (3)
- Examining Side Effect Variability of Antipsychotic Treatment in Schizophrenia Spectrum Disorders: A Meta-analysis of Variance. (2021) (3)
- MDL 27,531 reduces spontaneous hindlimb contractions in rats with chronic transections of the spinal cord (1992) (3)
- Reducing Nonadherence: New Formulations of Antipsychotic Medications (2006) (3)
- Low Dose Fluphenazine Decanoate in Treatment of Schizophrenia (1979) (3)
- Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations (2021) (3)
- Clozapine Management in Schizophrenia Inpatients: A 5-Year Prospective Observational Study of Its Safety and Tolerability Profile (2021) (3)
- MCPH1 is associated with risk for illness and cognitive ability in patients with schizophrenia (2007) (3)
- Long-acting risperidone microspheres for treatment of patients with schizophrenia (2001) (3)
- Response to Fuchs (1994) (3)
- Clinical and computational speech measures are associated with social cognition in schizophrenia spectrum disorders (2022) (3)
- Dr. Zimbroff and Colleagues Reply (1998) (3)
- P.3.c.018 A placebo-controlled study of efficacy/safety of aripiprazole intramuscular depot for long-term maintenance treatment of schizophrenia (2012) (3)
- The anhydro-5-hydroxy-1,3-oxathiolium hydroxide system, a new mesoionic ring system (1975) (3)
- P.3.a.015 Efficacy and safety of olanzapine long-acting injection for maintenance treatment of schizophrenia (2008) (3)
- Methylation of 2,4-dihydro-3H-1,2,4-triazol-3-ones. A structural determination of anhydro-5-aryl-1,4-dimethyl-3-hydroxy-1,2,4-triazolium hydroxides by two dimensional NMR (1990) (3)
- Making Sense of the Matrix: A Qualitative Assessment and Commentary on Connecting Psychiatric Symptom Scale Items to the Research Domain Criteria (RDoC). (2022) (3)
- Digital and Mobile Health Technology in Collaborative Behavioral Health Care: Scoping Review (2022) (3)
- How to Make an Effective Offer of Clozapine. (2021) (3)
- Clozapine And Weight Gain - Association With Clinical Response And Long-Term Course (1994) (3)
- Assessing and measuring nonresponse in schizophrenia. (2012) (3)
- New developments in the pharmacological treatment of schizophrenia. (1992) (2)
- Cardiac risk factors and schizophrenia: An analysis of 18,094 patients enrolled in an international comparative trial of olanzapine and ziprasidone (2007) (2)
- Withdrawal Syndrome Following Discontinuation of 28 Antidepressants: Pharmacovigilance Analysis of 31,688 Reports from the WHO Spontaneous Reporting Database (2022) (2)
- 2277 – A Placebo-controlled Study Of Efficacy And Safety Of Aripiprazole Once-monthly For Long-term Maintenance Treatment In Schizophrenia (2013) (2)
- Clozapine once- versus multiple-daily dosing: a two-center cross-sectional study, systematic review and meta-analysis. (2022) (2)
- DYSGLYCEMIC SIGNALS IN CHILDREN AND ADOLESCENTS TREATED WITH ANTIPSYCHOTICS FOR THE FIRST TIME (2014) (2)
- P.3.d.028 Personal and social performance in schizophrenia: double-blind, non-inferiority study of once-monthly vs oral aripiprazole (2013) (2)
- Clinical insights into pharmacogenetics and schizophrenia, part 2. (2008) (2)
- United States: Neuroleptic Relapse Prevention (1991) (2)
- Ziprasidone in Schizophrenia: From Acute Treatment to Long-Term Management (2003) (2)
- Long-acting injectable versus oral antipsychotics for schizophrenia - Authors' reply. (2021) (2)
- MDL 27,266: A broad spectrum anticonvulsant triazol-3-one (1990) (2)
- Issues in psychopharmacology. (2007) (2)
- Alternative treatments for non-responding patients (1992) (2)
- Acoustic and Facial Features From Clinical Interviews for Machine Learning–Based Psychiatric Diagnosis: Algorithm Development (2022) (2)
- ISSUES IN CLINICAL TRIAL DESIGNS (2002) (2)
- Cerebrospinal fluid met5-enkephalin-arg6-gly7-leu8 immunoreactive peptides: differential effect of haloperidol compared to clozapine (1989) (2)
- Commentary on the clozapine conflict. (1996) (2)
- S.05.02 Early response as a response predictor: use of individual variability in clinical trials (2009) (2)
- The facilitation of early detection and treatment of schizophrenia (1997) (2)
- The value of risk reduction in CNS drug development: use of expected net present value (eNPV) as a model (2013) (2)
- Risperidone long-acting injection (2004) (2)
- Impact of recent economic changes in psychiatry on academic psychiatry programs. (1996) (2)
- Prolactin changes during electroconvulsive therapy: A systematic review and meta-analysis. (2020) (2)
- Reply to Comments by Drs Rickels and Robinson (2007) (2)
- Approaches to Treatment‐Resistant Patients (2011) (2)
- Tardive dyskinesia induced by risperidone? [9] (1996) (2)
- Long acting injectable vs. oral antipsychotics in schizophrenia: A systematic review and meta-analysis of cohort studies (2014) (2)
- Effectiveness of a Cognitive Behavioral Weight Management Intervention in Obese Patients with Psychotic Disorders Compared to Patients with Non-Psychotic Disorders or No Psychiatric Disorders: Results from a 12-month, Real-World Study (2019) (2)
- Early Intervention Services 2.0: Designing Systems for the Next Generation of Work (2020) (2)
- The use of scales for clinical monitoring of disease progression and the treatment of schizophrenia. (1997) (2)
- Elevated Blood Urea Nitrogen and Medical Outcome of Psychiatric Inpatients (2014) (2)
- Tardive dyskinesia workgroup report. (1980) (2)
- M16. Valbenazine (nbi-98854) for the Treatment of Tardive Dyskinesia: Analysis by Underlying Psychiatric Diagnosis in Phase Iii Kinect 3 Study (2017) (2)
- New developments in the pharmacologic treatment of schizophrenia: editor's introduction. (1993) (2)
- Clozapine and COVID-19/respond (2020) (2)
- Heterocyclic guanidines as calcium antagonists (1994) (2)
- Tolerability of clozapine and risperidone during a twenty nine week trial (2003) (2)
- P.3.c.019 Psychosocial and overall effectiveness of aripiprazole intramuscular depot vs. placebo for maintenance treatment in schizophrenia (2012) (2)
- Functional Outcomes with Aripiprazole Once-Monthly in Two Double-Blind, Placebo- and Active-Controlled Studies (Aspire US 246 and Aspire EU 247) for the Treatment of Schizophrenia (2013) (2)
- 185 The Safety and Tolerability of Lumateperone 42 mg for the Treatment of Schizophrenia: A Pooled Analysis of 3 Randomized Placebo-Controlled Trials (2020) (2)
- Psychopharmacologic issues in the maintenance treatment of schizophrenia. (1984) (2)
- Clinical and Cost Implications of Treating Schizophrenia: Safety, Efficacy, Relapse Prevention, and Patient Outcomes (2014) (2)
- Dr. Jeste and Colleagues Reply (2001) (2)
- PM421. Efficacy and safety of brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies (2016) (2)
- H-19F NOE difference spectroscopy as a tool for structural assignment of positional isomers in fluorine-substituted analogues of FPL 64176 (1997) (2)
- Development of drug-induced parkinsonism in elderly individuals receiving neuroleptics for the first time (1991) (2)
- Relapse prevention through health technology program reduces hospitalization in schizophrenia (2019) (2)
- O6.4. GOOGLE SEARCH ACTIVITY IN EARLY PSYCHOSIS: A QUALITATIVE ANALYSIS OF INTERNET SEARCH QUERY CONTENT IN FIRST EPISODE PSYCHOSIS (2019) (2)
- 43. Cognitive Functioning in First-Episode Psychosis:_x000B_ Comparison of a 2-Year Coordinated Specialty Care Program to Community Care (2017) (2)
- THE ZIPRASIDONE OBSERVATIONAL STUDY OF CARDIAC OUTCOMES (ZODIAC): FINDINGS FROM A LARGE SIMPLE TRIAL OF ZIPRASIDONE VS. OLANZAPINE IN REAL-WORLD USE AMONG 18154 PATIENTS WITH SCHIZOPHRENIA (2010) (2)
- The Reintegration Journey Following a Psychiatric Hospitalization: Examining the Role of Social Technologies (2022) (2)
- Natural History, Not Lead Time: Response to Srihari et al. (2020) (1)
- Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management. (2003) (1)
- Corrigendum to “The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: A pooled analysis of data from the pivotal trials” [Schizophrenia Research 105 (2008) 208–215] (2009) (1)
- Chapter 6 - Seven-Membered Rings (1990) (1)
- Antipsychotic drug therapy: current status. (1996) (1)
- Studies of maintenance pharmacotherapy in schizophrenia: the Hillside Series. (1982) (1)
- SU14. Characteristics Associated With Relapse in Patients With Schizophrenia: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Cariprazine Relapse Prevention Trial (2017) (1)
- Performance improvement CME: managing schizophrenia. (2011) (1)
- Corrigendum to “Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies” [Schizophr. Res. 174 (2016) 82–92] (2017) (1)
- Striatal Functional Connectivity in Psychosis Relapse: A Comparison Between Antipsychotic Adherent and Non-Adherent Patients at the Time of Relapse (2020) (1)
- P.3.d.037 Effects of aripiprazole once-monthly in patients with schizophrenia switched from oral antipsychotics to aripiprazole once-monthly (2014) (1)
- Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics and Telepsychiatry Use During COVID-19 Pandemic (2022) (1)
- Identification of a 4H‐benz[f]indole by‐product from the friedel‐crafts‐based synthesis of benzoylpyrrole calcium channel activators (1993) (1)
- CHAPTER 11 – ACUTE TREATMENT (1993) (1)
- Internet Search Activity of Young People With Mood Disorders Who Are Hospitalized for Suicidal Thoughts and Behaviors: Qualitative Study of Google Search Activity (2021) (1)
- 525 Effectiveness of clozapine in treatment resistant schizophrenia (1997) (1)
- Reply to Weight Gain and Antipsichotics. (2005) (1)
- Subject Index Vol. 10, 1983 (1983) (1)
- Antipsychotic Medications: Enhancing Use to Improve Outcomes. (2021) (1)
- Response to Amos: Addressing Purported Methodological Flaws in RAISE-ETP Results. (2016) (1)
- T205. LUMATEPERONE IN THE TREATMENT OF SCHIZOPHRENIA: EVALUATION OF EXTRAPYRAMIDAL AND MOTOR SYMPTOMS IN 4 LATE-PHASE CLINICAL TRIALS (2020) (1)
- Outcomes During and After Early Intervention Services for First-Episode Psychosis: Results Over 5 Years From the RAISE-ETP Site-Randomized Trial. (2022) (1)
- P.3.d.027 Aripiprazole once-monthly for schizophrenia: a double-blind, randomised, non-inferiority study versus oral aripiprazole (2013) (1)
- Predictors for Initiation of Atypical Long-Acting Injectable Antipsychotic Agents in a Commercial Claims Cohort of Individuals With Early-Phase Schizophrenia. (2023) (1)
- Examining side effect variation in antipsychotic treatment and schizophrenia spectrum disorders (2020) (1)
- C.03.03 Efficacy of aripiprazole-IM-depot in the treatment of schizophrenia (2012) (1)
- Neuroendocrine responses in diagnostic groups. (1982) (1)
- 119. The Pharmacologic Treatment of Schizophrenia: How Far Have We Come (2017) (1)
- Clozapine and risperidone in moderately refractory schizophrenia: A six month double-blind comparison (2003) (1)
- Regional disease characteristics and comorbidities of patients with schizophrenia in the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): Findings from an international large simple trial (2012) (1)
- Early versus late administration of long-acting injectable antipsychotic agents among patients with newly diagnosed schizophrenia: an analysis of a commercial claims database. (2023) (1)
- LACK OF EARLY IMPROVEMENT DEMONSTRATES STRONG NEGATIVE PREDICTIVE VALUE FOR LATER TREATMENT RESPONSE WITH ATYPICAL ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA (2009) (1)
- SA17. Response to Treatment With Valbenazine (NBI-98854) in Subjects With Tardive Dyskinesia. (2017) (1)
- An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s (2022) (1)
- Dr Correll and Colleagues Reply. (2017) (1)
- Biologic, pharmacologic, and psychosocial factors influencing response to neuroleptics. (1992) (1)
- P.3.d.037 Hospitalization rates in patients switched from oral antipsychotics to aripiprazole once-monthly for schizophrenia (2013) (1)
- Reply to the Comments by Doherty et al. (2020) (1)
- P.3.d.072 Efficacy and safety of brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies (2015) (1)
- Lead-Time Bias as a Potential Explanation for the Link Between Duration of Untreated Psychosis and Outcome: Response to Iyer et al. (2020) (1)
- Synthesis of FPL 64176 by 1,3-Dipolar Cycloaddition. (1995) (1)
- Building sustainable SBIRT in an integrated hospital system in New York (2015) (1)
- In Response to Healy (2003) (1)
- FPL 64176 : THE EFFECT OF THE CHAIN LENGTH SEPARATING THE TWO ARYL GROUPS ON CALCIUM AGONIST ACTIVITY (1995) (1)
- Performance improvement CME: schizoaffective disorder. (2011) (1)
- Dr. Correll and Colleagues Reply (2005) (1)
- Ethics of Drug Discontinuation Studies in Schizophrenia-Reply (1989) (1)
- Poster #S233 ALL-CAUSE DISCONTINUATION AND SAFETY OF ARIPIPRAZOLE ONCE-MONTHLY FOR THE TREATMENT OF SCHIZOPHRENIA: A POOLED ANALYSIS OF TWO DOUBLE-BLIND, RANDOMIZED, CONTROLLED TRIALS (2014) (1)
- DIFFERENCES BETWEEN EARLY RESPONDERS AND EARLY NON-RESPONDERS TO ATYPICAL ANTIPSYCHOTICS ON SYMPTOM AND FUNCTIONAL OUTCOMES IN THE TREATMENT OF SCHIZOPHRENIA (2010) (1)
- Sudden death in psychiatric patients (2011) (1)
- Dr. Rifkin and Associates Reply (1986) (1)
- Objective User Engagement With Mental Health Apps: Systematic Search and Panel-Based Usage Analysis (Preprint) (2019) (1)
- Implications for health and disease in the genetic signature of the Ashkenazi Jewish population (2012) (1)
- Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension (2022) (1)
- Corrigendum (2017) (1)
- Clozapine Response In Chronic Schizophrenia And Brain Morphology On MRI: A Preliminary Report (1994) (1)
- Often claimed, rarely tested: differences in individual drug response (2018) (1)
- 330. Atypical antipsychotic effects on fMRI in drug-naive schizophrenia (2000) (1)
- Clinical implications of Brief Psychiatric Rating Clinical implications of Brief Psychiatric Rating (2005) (1)
- Duration of Untreated Psychosis: Getting Both the Timing and the Sample Right: Response to Woods et al. (2020) (1)
- Lack of ECT effects on clozapine plasma levels in patients with treatment-resistant schizophrenia: Pharmacokinetic evidence from a randomized clinical trial (2020) (1)
- Effects of Long-Term Valbenazine on Tardive Dyskinesia and Patient-Reported Outcomes: Results from the KINECT 4 Study (P4.078) (2018) (1)
- Alternative strategies for treating neuroleptic nonresponsive patients (1993) (1)
- Reading reports of clinical trial results. (2005) (1)
- A heterocyclic analog of leucine-enkephalin (1987) (1)
- Comment on: Tardive dyskinesia circa 2006. Author's reply (2007) (1)
- The Reactions of Thiosemicarbazides and 5-Halovalerophenones. (1989) (0)
- Telepsychiatry Satisfaction Survey (2021) (0)
- NO . 3 , 1996 Medical Complications of New Antipsychotic Drugs (2005) (0)
- Target dimensions in prediction of neuroleptic response: concepts and instruments (1994) (0)
- 48-1 Extrapyramidal signs in dyskinesia in first episode schizophrenia (1997) (0)
- The pharmacological treatment of schizophrenia: How far have we come? (2022) (0)
- THE EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF MULTIPLE SCHIZOPHRENIA SYMPTOMS DOMAINS: A POOLED ANALYSIS OF DATA FROM PIVOTAL TRIALS (2008) (0)
- A rare deletion at distal 16 p 11 . 2 is implicated in schizophrenia (2013) (0)
- 81. Relationship Between Untreated Psychosis and Intrinsic Corticostriatal Connectivity in Patients With Recent-Onset Schizophrenia (2017) (0)
- Marshes (2017) (0)
- New useful in the treatment of allergic diseases substituted piperidines (1997) (0)
- SCHIZOPHRENIA RESEARCH: THE CHALLENGE OF MEASUREMENT VARIABILITY (2014) (0)
- Disturbing Lack of Early Intervention Studies in Bipolar Disorder-Reply. (2018) (0)
- Anterior cingulate grey-matter deficits Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia and cannabis use in first-episode schizophrenia (2007) (0)
- Clozapine Optimization: A Delphi Consensus Guideline From the Treatment Response and Resistance in Psychosis Working Group. (2023) (0)
- O12.6. LONG-TERM EFFECTS OF VALBENAZINE ON TARDIVE DYSKINESIA IN PATIENTS WITH SCHIZOPHRENIA/SCHIZOAFFECTIVE DISORDER: RESULTS FROM AN OPEN-LABEL, ROLLOVER STUDY (2019) (0)
- Internet Search Activity of Young People With Mood Disorders Who Are Hospitalized for Suicidal Thoughts and Behaviors: Qualitative Study of Google Search Activity (Preprint) (2021) (0)
- Replication of Genetic Markers Associated with Clozapine-Induced Agranulocytosis. (2006) (0)
- 130. Meta-Analysis of Tardive Dyskinesia Rates in Randomized Controlled Studies Comparing First- to Second-Generation Antipsychotics (2017) (0)
- Editorial: Schizophrenia International Research Society (2006) (0)
- The Management of Schizophrenia: Safety, Treatment, and Continuity of Care (2007) (0)
- The Relationship Between Acoustic Startle Response Measures and Cognitive Functions in Japanese Patients with Schizophrenia (2012) (0)
- F198. Parahippocampal Thickness Predicts Treatment Improvement in Early and Chronic Schizophrenia (2018) (0)
- Co-occurrence of clozapine-related DRESS syndrome core clinical manifestations: results of a systematic review (2022) (0)
- S-42-1 Placebo response in schizophrenia (1996) (0)
- WITHDRAWN: Corrigendum to “Dose and safety concerns of clozapine: Worldwide package inserts need revisions” [Schizophr. Res. 08619] (2020) (0)
- 5-aryl-2,4-dialkyl-3H-1,2,4-triazole-3-thiones, to their preparation and to their use for the preparation of agents antipedressive (1986) (0)
- P.461 Behavioral economics to improve medication adherence in severe mental illness: A systematic review of current evidence (2019) (0)
- Substituted piperidines for the treatment of allergic diseases (1995) (0)
- The criteria for evaluating response to antipsychotics in schizophrenia (2000) (0)
- Treatment Compliance and Outcome With Atypical Antipsychotics (1970) (0)
- Prescribing clozapine in the UK: Quality improvement issues identified by clinical audit (2022) (0)
- The treatment of schizophrenia in the next decades (2000) (0)
- P.3.d.034 Effects of aripiprazole once-monthly on functioning in patients with schizophrenia (2014) (0)
- O5.5. PSYCHOTIC RELAPSE DURING MAINTENANCE ANTIPSYCHOTIC TREATMENT: A NATIONWIDE STUDY (2019) (0)
- Distinguishing the Effects of Lead-Time Bias and Duration of Untreated Psychosis. (2022) (0)
- GREATER CORTICAL THICKNESS IN PATIENTS WITH FIRST-EPISODE SCHIZOPHRENIA WHO ARE RESPONSIVE TO ATYPICAL ANTIPSYCHOTICS (2008) (0)
- Psychopharmacologic Treatment of Schizophrenia 287 by (2005) (0)
- 5‐Aryl‐3‐(alkylthio)‐4H‐1,2,4‐triazoles as Selective Antagonists of Strychnine‐Induced Convulsions and Potential Antispastic Agents. (1994) (0)
- Financial incentives improve adherence to maintenance antipsychotic treatment (2014) (0)
- post hoc analysis of pooled data from short-and long-term aripiprazole trials Evaluation of akathisia in patients with schizophrenia , schizoaffective disorder , or bipolar I disorder : a (2010) (0)
- S.06.01 The treatment of the schizophrenic patient: How far have we come in meeting the challenge (1996) (0)
- Drs Kane and Correll Reply. (2020) (0)
- C.05.03 The role of novel atypical depot formulations in helping to improve long-term outcomes in schizophrenia (2011) (0)
- Examining Predictors of Real-World User Engagement with Self-Guided eHealth Interventions: Analysis of Mobile Apps and Websites Using a Novel Dataset (Preprint) (2018) (0)
- The differential diagnosis of schizoaffective disorder. (2010) (0)
- Teaching and practicing psychopharmacology. (2007) (0)
- Psychopharmacologic treatment issues. (1990) (0)
- Psychiatrists' perceptions of medication adherence among patients with schizophrenia: An international survey (2019) (0)
- Heterocyclic Guanidines as Calcium Antagonists. (1994) (0)
- Contents, Vol. 8, 1982 (1982) (0)
- PYRROLO(1,2-C)THIAZOLE, A RING-FUSED NONCLASSICAL THIAZOLE SYSTEM (1981) (0)
- Aripiprazole for the Treatment of Schizophrenia--Selected Posters (2008) (0)
- P.556 Long-acting injectable vs. oral antipsychotics for preventing rehospitalisation in schizophrenia: a meta-analysis of randomised, mirror-image, and cohort studies (2020) (0)
- An Extremely Short Synthesis of Benzoylpyrrole‐Type Calcium Channel Activators. (1993) (0)
- Comparative effectiveness of oral antipsychotics and long-acting injectable antipsychotics (2016) (0)
- Seven‐Membered (Heterocyclic) Rings (1992) (0)
- Future Directions in Schizophrenia Research (1993) (0)
- Corrigendum to “Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: A randomized, double-blind, active parallel-controlled, multicenter clinical trial” [Schizophr. Res. 157 (1–3) (August 2014) 112–119] (2014) (0)
- Edentulousness in severely mentally ill patients: A pilot study of sex-specific patterns for risk factors including the glutathione S-transferase M1 gene (2020) (0)
- TO THEEDITOR: Inagreement withDr. Saraga, we wouldvery much like to interview the prescribers of the medications recordedinoursurveyabouttheirprescribingdecisions.They werenot,asDr.Saragasuggests,"physiciansintheRAISE-ETP (2015) (0)
- Methylation of 2,4-Dihydro-3H-1,2,4-triazol-3-ones. A Structural Determination of Anhydro-5-aryl-1,4-dimethyl-3-hydroxy-1,2,4- triazolium Hydroxides by Two-Dimensional NMR. (2010) (0)
- S-24-1 Important factors in long-term maintenance therapy (1996) (0)
- T23. ANTIPSYCHOTIC EXPOSURE AND STRIATAL FUNCTIONAL CONNECTIVITY IN PSYCHOSIS RELAPSE: A HYPOTHESIS GENERATING STUDY (2020) (0)
- Implementation of NAVIGATE Coordinated Specialty Care for First Episode Psychosis: the Michigan Experience. (2021) (0)
- Contents, Vol. 10, 1983 (1983) (0)
- Identification of a 4H‐Benz(f)indole By‐Product from the Friedel‐ Crafts‐Based Synthesis of Benzoylpyrrole Calcium Channel Activators. (1993) (0)
- T216. VARIATION IN SIDE EFFECTS TO ANTIPSYCHOTIC TREATMENT ACROSS SCHIZOPHRENIA SPECTRUM DISORDERS (2020) (0)
- Tardive dyskinesia in affective disorders. Discussion (1999) (0)
- P.3.d.031 The appropriate pharmacological management of recent-onset schizophrenia: an international panel study using the RAND/UCLA methodology (2016) (0)
- Cultural Influences in Psychiatry-Reply. (2020) (0)
- C.05.03 Do current treatment options differ in terms of functioning and quality of life outcomes in schizophrenia? (2015) (0)
- A Highly Convergent Synthesis of Benzimidazoloylpiperidines. (1990) (0)
- Maintenance Strategies in Schizophrenia (2010) (0)
- Adoption of Digital Health Technologies in the Practice of Behavioral Health: Qualitative Case Study of Glucose Monitoring Technology (Preprint) (2020) (0)
- Often claimed, rarely tested: individual drug response in antipsychotic drug trials (2018) (0)
- Contingency planning and risk mitigation strategies for a schizophrenia relapse prevention trial during the COVID-19 pandemic (2022) (0)
- The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence|J Clin Psychiatry (2020) (0)
- Delphi Panel on the Dimensions and Assessment of Functional Recovery in First-Episode and Early-Phase Schizophrenia Patients (2023) (0)
- P.3.d.037 Optimising response to lurasidone in patients with acute schizophrenia: A randomised, double-blind, placebo-controlled study of dosing regimens (2015) (0)
- fMRI motor effects of atypical antipsychotics in drug-naive schizophrenia (2000) (0)
- Reply to Comments by Grunze et al (2009) (0)
- EXPERT REVIEW SUPPLEMENT PRACTICAL DOSING STRATEGIES IN THE TREATMENT OF SCHIZOPHRENIA AUTHORS (2010) (0)
- S-10-1 Has the response of positive symptoms to antipsychotics changed? (1995) (0)
- P.3.f.006 Efficacy of lurasidone in schizophrenia: a systematic review and meta-analysis of short-term trials utilizing active comparator (2016) (0)
- Digital Strategies to Accelerate Help-Seeking in Youth With Psychiatric Concerns in New York State (2022) (0)
- An Improved Method for the Synthesis of 5‐Aryl‐3‐methyl‐2‐methylimino‐ 1,3,4‐oxadiazoles. (1992) (0)
- Current problems with the pharmacotherapy of schizophrenia. Discussion (1995) (0)
- Remission in schizophrenia: Where should the bar be set? (2007) (0)
- Computerized neurocognitive assessment: Clinical trials and FMRI applications (2003) (0)
- isrupted in Schizophrenia 1 Genotype and Positive ymptoms in Schizophrenia (2007) (0)
- O9.7. TECHNOLOGY ASSISTED RELAPSE PREVENTION PROGRAM REDUCES HOSPITALIZATION IN SCHIZOPHRENIA PATIENTS AT HIGH RISK FOR RELAPSE (2020) (0)
- 3-aryl-4-alkyl and 4,5-dialkyl-1,2,4-triazoles 4h-improvers useful as memory. (1994) (0)
- Salts of 3-phenyl-1,4-dialkyl-1,2,4-triazolium and their use as antidepressants. (1996) (0)
- P.0760 Prevalence of atypical antipsychotic use among patients with schizophrenia in the United States: an analysis of a commercial claims database (2021) (0)
- Mr. Wegner and Associates Reply (1978) (0)
- Predictors of Tardive Dyskinesia in First Episode Schizophrenia (1994) (0)
- Digital Technology In Psychiatry: Expectations, Barriers And Understanding Of Clinicians (Preprint) (2021) (0)
- Clozapine and COVID-19: The authors respond. (2020) (0)
- C.05.01 Clinical presentation of treatment-resistant schizophrenia (TRS) (2017) (0)
- Reply: To PMID 24354448. (2014) (0)
- Neuromuscular effects of monoamine oxidase inhibitors. (1986) (0)
- Neuroleptic-Induced Movement Disorders: Development of novel antipsychotic drugs with reduced extrapyramidal side effects (1996) (0)
- DIFFERENCES BETWEEN EARLY RESPONDERS AND EARLY NON-RESPONDERS TO ATYPICAL ANTIPSYCHOTICS ON FUNCTIONAL OUTCOMES IN THE TREATMENT OF SCHIZOPHRENIA (2009) (0)
- P 0262 Risperidone and liver function tests in children and adolescents : A short term prospective study (0)
- CPNP 2019 Annual Meeting Poster Abstracts (2019) (0)
- UNDERSTANDING PATHWAYS TO CARE AS A MEANS OF ADVANCING EARLY INTERVENTION: FINDINGS FROM AROUND THE WORLD (2014) (0)
- C.07.04 Is there a sense of urgency to optimise relapse prevention and functioning in patients with schizophrenia? (2019) (0)
- [Clozapine in the treatment of schizophrenia]. (1991) (0)
- P.3.c.041 Relapse prevention in schizophrenia: 12 month treatment with lurasidone versus quetiapine extended release among responders to acute treatment (2012) (0)
- PRACTICAL DOSING STRATEGIES IN THE TREATMENT OF SCHIZOPHRENIA (2010) (0)
- Psychoeducation for Inpatients With First-Episode Psychosis: Results From a Survey of Psychiatry Trainees in New York City. (2021) (0)
- C.01.03 Sustained remission as new standard for outcome in schizophrenia, changing longterm prognosis earlier in its course (2006) (0)
- Reply (2014) (0)
- Lessening the Side Effect Burden to Improve Adherence Among Individuals With Schizophrenia. (2021) (0)
- Inverse relationship between body mass index and mortality in older nursing-home residents: A collaborative meta-analysis of 19,538 elderly subjects (2016) (0)
- Akathisia and Restless Legs: Foreword (1995) (0)
- P.3.d.067 Long-acting injectable vs oral antipsychotics for hospitalisation prevention in schizophrenia: a systematic review/meta-analysis of cohort studies (2015) (0)
- A Heterocyclic Analog of Leucine-Enkephalin. (1987) (0)
- Derives piperidinyles thiacycliques (1993) (0)
- Synthesis and pharmacology of 3-aryl-5,6-dihydro-6-oxo-1(4H)-pyridazineacetic acid derivatives. (1992) (0)
- Long-acting antipsychotics: is what we know really so? - Authors' reply. (2021) (0)
- P.3.c.060 Differences in early responders/early non-responders to atypical antipsychotics on functional outcomes in schizophrenia (2008) (0)
- THE REACTION OF 4-ALKYL-3-THIOSEMICARBAZIDES WITH β-HALO KETONES (1984) (0)
- The Affordable Care Act and Practice in Psychiatry (2013) (0)
- Predictors of Hospitalization with Individuals With First-Episode Psychosis: Data From a Two-Year Follow-Up in the RAISE-ETP Study (2019) (0)
- Digital Technology in Psychiatry: Survey Study of Clinicians (2022) (0)
- P.445 Dose-response relationships of antipsychotic drugs for major depressive disorder: a systematic review and meta-analysis (2020) (0)
- Delphi panel on management, treatment goals and functional recovery with long-acting injectable antipsychotics in first episode and early phase schizophrenia (2022) (0)
- Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS (2023) (0)
- Relapse prevention through health technology program reduces hospitalization in schizophrenia. (2022) (0)
- Author response for "A Systematic Review and Pooled, Patient‐Level Analysis of Predictors of Mortality in Neuroleptic Malignant Syndrome" (2021) (0)
- DIGITAL TECHNOLOGY IN PSYCHIATRY: A SURVEY STUDY ON EXPECTATIONS, BARRIERS AND UNDERSTANDING OF CLINICIANS (Preprint) (2021) (0)
- Validation of a novel Psychosis-Implicit Association Test (P-IAT) as a diagnostic support tool (2022) (0)
- S0033291720004584jra 2606..2613 (2022) (0)
- Dispelling myths and misconceptions surrounding the use of long-acting injectable antipsychotic agents for treatment of schizophrenia (2022) (0)
- Dr. Nielsen and colleagues reply. (2015) (0)
- A Digital Intervention Using Daily Financial Incentives to Increase Medication Adherence in Severe Mental Illness: Single-Arm Longitudinal Pilot Study (2022) (0)
- Delphi Panel on the Relationship Between Long-Acting Injectable Antipsychotics and Longer-Term Functional Recovery in First-Episode and Early-Phase Schizophrenia Patients (2023) (0)
- Music in behavioral health: from digital biomarker to therapeutics (2021) (0)
- The place of long-acting injectable antipsychotics in the treatment of schizophrenia (2023) (0)
- The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia (2023) (0)
- Digital and Mobile Health Technology in Collaborative Behavioral Health Care: Scoping Review (Preprint) (2021) (0)
- Cross-Platform Detection of Psychiatric Hospitalization via Social Media Data: Comparison Study (2022) (0)
- Do Clinicians Need to Rethink Antipsychotic Maintenance Treatment? (2022) (0)
- Post-acute college student satisfaction with telepsychiatry during the COVID-19 pandemic (2022) (0)
- 2281 – Psychosocial And Overall Effectiveness Of Aripiprazole Once-monthly Vs. Placebo Once-monthly For Maintenance Treatment In Schizophrenia (2013) (0)
- P.3.f.007 Safety of lurasidone in schizophrenia: a systematic review and meta-analysis of short-term trials utilizing active comparator (2016) (0)
- FC13-10 - Frequency of prolonged qtc in children and adolescents hospitalized for psychiatric disorders: a nested case-control study (2011) (0)
- Writing Proofs in Analysis (2016) (0)
- Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis. (2021) (0)
- NDT_A_310605 1589..1597 (2021) (0)
- Mega-review of meta-analyses investigating the short-term efficacy of pharmacologic augmentation strategies of antipsychotics in patients with schizophrenia (2016) (0)
- Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: Treatment goals and approaches to functional recovery (2023) (0)
- Treatment Journey From Diagnosis to the Successful Implementation of a Long-Acting Injectable Antipsychotic Agent in Young Adults With Schizophrenia. (2023) (0)
- Bipolar Prodrome Symptom Scale--Retrospective Version (2020) (0)
- Assessment of akathisia in acute schizophrenia and schizoaffective disorder patients: A pooled analysis of 5 placebo-controlled, double-blind studies with aripiprazole (2007) (0)
- Impact-Tardive Dyskinesia (Impact-TD) Scale: A Clinical Tool to Assess the Impact of Tardive Dyskinesia. (2022) (0)
- C.01.02 Individualisation of treatment in schizophrenia (2019) (0)
- Contents of the American Journal of Psychiatry (2004) (0)
- Academic Highlights: New Developments in the Treatment of Schizophrenia. [CME] (2007) (0)
- Olanzapine/Samidorphan in Young Adults With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness: Results of the Randomized, Controlled ENLIGHTEN-Early Study. (2023) (0)
- New-Onset Schizophrenia: Pharmacologic Treatment (2008) (0)
- Lithium response in acute adolescent mania (2000) (0)
- Acoustic and Facial Features From Clinical Interviews for Machine Learning–Based Psychiatric Diagnosis: Algorithm Development (Preprint) (2020) (0)
- C.04.01 Protecting patients from the long-term consequences of schizophrenia (2013) (0)
- Piperidinilos tiaciclicos derivatives. (1993) (0)
- Antenatal Antidepressant Prescription Associated With Reduced Fetal Femur Length but Not Estimated Fetal Weight (2021) (0)
- PHARMACEUTICAL PIPELINE SESSION (2014) (0)
- Long-Term Treatment of Schizophrenia (1996) (0)
- New enkephalin derivatives (1980) (0)
- Enkaphalinderivater their preparation and use as analgesics, and antipsychotics intermediates therefor and their preparation (1980) (0)
- Reply to Orally Distegrating Antipsychotics May Promote Compliance and Adherence in Patients With Schizophrenia (2005) (0)
- P.3.d.007 Efficacy of cariprazine on PANSS items and Marder factors: post hoc analysis of a double-blind, placebo-controlled trial in schizophrenia (2013) (0)
- COMPARISON OF REMISSION RATES AND TOLERABILITY IN PATIENTS WITH EARLY-EPISODE SCHIZOPHRENIA RECEIVING ARIPIPRAZOLE OR HALOPERIDOL (2008) (0)
- The Treatment of Early Phase Schizophrenia: Improving Outcomes (2019) (0)
- Questioning DST normalization as a guide to tricyclic discontinuation. (1983) (0)
- Poster #208 NEW RESULTS ALTER BALANCE OF EVIDENCE IN META-ANALYSIS OF LONG-ACTING INJECTABLE VS. ORAL ANTIPSYCHOTICS IN SCHIZOPHRENIA (2012) (0)
- Authors' reply (2009) (0)
- Standard v Optimal Dose-Reply (1984) (0)
- Drug Evaluation Central & Peripheral Nervous Systems Olanzapine (Zyprexa): characteristics of a new antipsychotic (1997) (0)
- A process for preparing 5-aryl-2,4-dialquiil-3h-1,2, 3-thiones triazolo-. (1986) (0)
- Activation tasks in neuroleptic-induced akathisia (1991) (0)
- Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder (1990) (0)
- Residual and negative symptoms in treatment with neuroleptics. (1993) (0)
- Transitioning from acute to long-term treatment in schizophrenia. (2011) (0)
- S-19-5 Assessment of negative symptoms in the long-term treatment of psychosis (1995) (0)
- 178.2 Developing Strategies to Reduce DUP in the Age of Social Media and the Internet. (2017) (0)
- O8.2. VALIDATION OF A COMPUTERIZED ADAPTIVE TESTING TOOL FOR PSYCHOSIS: THE CAT-PSYCHOSIS BATTERY (2020) (0)
- Psychosis Relapse During Long-Acting Injectable Antipsychotic Treatment: An Individual Participant Data Meta-Analysis of 19 Trials and 5,111 Individuals with Schizophrenia-Spectrum Disorders (2020) (0)
- Graphic Design Primer (2005) (0)
- Subject Index Vol. 8, 1982 (1982) (0)
- Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic (2023) (0)
- Making the Link Between Science and Symptoms in Schizophrenia (2015) (0)
- Reasons for Antipsychotic Treatment Switch: A Systematic Retrospective Review of Prescription Records and Prescriber Notes. (2022) (0)
- Recent advances in treatments for schizophrenia. (2011) (0)
- Clinical dilemmas in schizophrenia treatment and the potential place in therapy of long-acting antipsychotic agents (2022) (0)
- Correction: An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. (2022) (0)
- Reply to Peterson-Dana and Palanci. (2020) (0)
- Synthesis of 3H-1,2,4-Thiadiazolo(3,4-b)benzothiazoles. (1990) (0)
- P.3.c.040 Ziprasidone and the QTc interval: a comprehensive review (2011) (0)
- Long‐Range Fluorine‐Proton Coupling in 1,2,4‐Triazole Derivatives. (1995) (0)
- Prospects for the Development of Safer Antipsychotic Agents for the Treatment of the Elderly (1985) (0)
- Adjunctive Armodafinil in Schizophrenia (2009) (0)
- New Clinical Drug Evaluation Unit (NCDEU) annual meeting: a great opportunity for early career psychiatrists. (2012) (0)
- P.320 Risk/benefit balance of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis (2020) (0)
- Illustrative case studies (2018) (0)
- Patient Attitudes Toward Telepsychiatry During the COVID-19 Pandemic: A Nationwide, Multisite Survey (Preprint) (2020) (0)
- P.3.d.046 Switching from oral antipsychotics to aripiprazole once-monthly in a naturalistic setting: hospitalisation rates from a mirror study (2014) (0)
- MDMA for the Treatment of Negative Symptoms in Schizophrenia (2022) (0)
- eurocognitive Profile in Adolescents with Early-Onset chizophrenia : Clinical Correlates (2005) (0)
- The valid assessment and diagnosis of akathisia is of great importance for antipsychotic treatment and for the evaluation of the side-effects of neuroleptics (2006) (0)
- Awareness of illness moderates self-assessment of psychotic symptoms (2021) (0)
- New in the treatment of allergic diseases and useful substituted piperidines (1997) (0)
- Gender differences in clozapine treated schizophrenic patients (1993) (0)
- Gauging the Scope for Precision Medicine: Evaluating Individual Differences in Side Effects to Antipsychotic Treatment (2020) (0)
- A process for preparing 3h-1,2,4-triazole-3-thiones substituted in position 5 by a heterocyclic group as well as its use as an antidepressant. (1986) (0)
- Longitudinal study of inflammation and relapse in schizophrenia (2023) (0)
- A process for the preparation of therapeutically useful new 3-aryl-5-sulfonyl and alkylsulfinyl-4H-1,2,4-triazoles (1988) (0)
- Schizophrenia International Research Society. (2007) (0)
- Management strategies for the treatment of schizophrenia : Current concepts and future prospects (1999) (0)
- Coping with a drug-induced movement disorder: tardive dyskinesia. (1982) (0)
- 20-4 Broadening perspective in the treatment of schizophrenia (1997) (0)
- Utilizing Machine Learning on Internet Search Activity to Support the Diagnostic Process and Relapse Detection in Young Individuals With Early Psychosis: Feasibility Study (Preprint) (2020) (0)
- Enkaphaline derivatives, their preparation and their therapeutic uses, in particular as analgesics (1980) (0)
- PMH51 THE COST-EFFECTIVENESS OF EARLY RESPONDERS VERSUS EARLY NON-RESPONDERS TO ATYPICAL ANTIPSYCHOTIC THERAPY (2010) (0)
- Poster #M263 CLOZAPINE PRESCRIPTION TO TREATMENT-RESISTANT SCHIZOPHRENIA PATIENTS IN COMMUNITY MENTAL HEALTH SERVICES IN SãO PAULO BRAZIL (2014) (0)
- Response to Saraga. (2015) (0)
- S-67-5 Lack of treatment and development of treatment refractoriness in schizophrenia (1996) (0)
- Academic Highlights: Clinical Insights Into Pharmacogenetics and Schizophrenia, Part 1 [CME] (2008) (0)
- Biochemical effects of clozapine in schizophrenia (1989) (0)
- News from the American Society of Clinical Psychopharmacology. (2005) (0)
- Authors’ Reply to Suhas et al.: Comment on: “Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation” (2021) (0)
- Process for the preparation of new competitive inhibitors of 3-aryl-5-alkylsulfinyl and sulfonyl-4H-1,2,4-triazoles (1988) (0)
- O10.8. STRIATAL CONNECTIVITY IN BREAKTHROUGH PSYCHOSIS ON ANTIPSYCHOTIC MAINTENANCE: PRELIMINARY RESULTS FROM THE BAMM STUDY (2019) (0)
- ARIPIPRAZOLE IN COMBINATION WITH RISPERIDONE OR QUETIAPINE: RESULTS FROM A 16-WEEK, RANDOMIZED, DOUBLE-BLIND STUDY IN SUBJECTS WITH SCHIZOPHRENIA (2008) (0)
This paper list is powered by the following services:
Other Resources About John M. Kane
What Schools Are Affiliated With John M. Kane?
John M. Kane is affiliated with the following schools:
